<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">76m3fkdH4hF3thh5fPwXDMB</article-id>
      <article-id pub-id-type="other">00021</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2010001500021</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(10)09500521</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2010001500021</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Correla&#231;&#227;o Anatomo-Cl&#237;nica</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Caso 5/2010: homem de 41 anos de idade portador de hipertrofia mioc&#225;rdica com evolu&#231;&#227;o para insufici&#234;ncia card&#237;aca congestiva</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Almeida</surname>
            <given-names>Rafael Moura de</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pires</surname>
            <given-names>Lucas Jos&#233; Tachotti</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Soares J&#250;nior</surname>
            <given-names>Jos&#233;</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ichiki</surname>
            <given-names>Wilson</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ichiki</surname>
            <given-names>Wilson Andr&#233;</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Demarchi</surname>
            <given-names>L&#233;a Maria Macruz Ferreira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">FM </institution>
        <institution content-type="orgdiv2">HC</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>10</month>
        <year>2010</year>
      </pub-date>
      <volume>95</volume>
      <issue>5</issue>
      <fpage>e112</fpage>
      <lpage>e121</lpage>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Insufici&#234;ncia card&#237;aca</kwd>
        <kwd>hipertrofia ventricular esquerda</kwd>
        <kwd>hipertens&#227;o</kwd>
        <kwd>fibrila&#231;&#227;o atrial</kwd>
        <kwd>amiloidose</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>13</day>
        <month>04</month>
        <year>2011</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>CORRELA&#199;&#195;O ANATOMO-CL&#205;NICA</bold>
    </p>
    <p>
      <bold>Caso 5/2010 - homem de 41 anos de idade portador de hipertrofia mioc&#225;rdica com evolu&#231;&#227;o para insufici&#234;ncia card&#237;aca congestiva</bold>
    </p>
    <p>
      <bold>Rafael Moura de Almeida; Lucas Jos&#233; Tachotti Pires; Jos&#233; Soares J&#250;nior; Wilson Ichiki; Wilson Andr&#233; Ichiki; L&#233;a Maria Macruz Ferreira Demarchi</bold>
    </p>
    <p>Instituto do Cora&#231;&#227;o (InCor) HC-FMUSP, S&#227;o Paulo, SP - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="end">Correspond&#234;ncia</xref>
    </p>
    <p><bold>Palavras-chave:</bold> Insufici&#234;ncia card&#237;aca; hipertrofia ventricular esquerda; hipertens&#227;o; fibrila&#231;&#227;o atrial; amiloidose.</p>
    <p>Homem de 41 anos, natural e procedente da cidade de S&#227;o Paulo, procurou atendimento em raz&#227;o de dispneia rapidamente progressiva e edema generalizado.</p>
    <p>O paciente sabia ser portador de hipertens&#227;o arterial e de hipertrofia de ventr&#237;culo esquerdo.</p>
    <p>O paciente era assintom&#225;tico at&#233; aos 33 anos de idade quando passou a apresentar dispneia aos esfor&#231;os. Procurou atendimento m&#233;dico na ocasi&#227;o e foi diagnosticado aumento da &#225;rea card&#237;aca. O quadro se manteve est&#225;vel at&#233; aos 35 anos (maio 2001) quando apresentou epis&#243;dio de palpita&#231;&#245;es taquic&#225;rdicas e dor precordial. Procurou atendimento m&#233;dico e foi feito o diagn&#243;stico de flutter atrial. O ecocardiograma (13 set 2001) revelou hipertrofia moderada de ventr&#237;culo esquerdo e derrame peric&#225;rdico moderado; a cineangiocoronariografia (18 out 2001) n&#227;o revelou les&#245;es obstrutivas nas art&#233;rias coron&#225;rias. Recebeu prescri&#231;&#227;o de amiodarona e foi encaminhado a este Hospital.</p>
    <p>O exame f&#237;sico (13 dez 2001) revelou frequ&#234;ncia card&#237;aca 68 bpm, press&#227;o arterial de 140/95 mmHg. O restante do exame f&#237;sico n&#227;o revelou outras altera&#231;&#245;es ou achados diagn&#243;sticos.</p>
    <p>O eletrocardiograma (18 dez 2001) revelou ritmo sinusal, frequ&#234;ncia 78 bpm, dura&#231;&#227;o do PR 157 ms, do QRS 108 ms, do QT 414 ms, S&#194;QRS + 130&#186; para tr&#225;s. A an&#225;lise morfol&#243;gica revelou onda P de amplitude aumentada, QS em deriva&#231;&#245;es I, aVL e onda Q em V6. Foram feitos os diagn&#243;sticos de sobrecarga atrial direita, &#225;rea eletricamente inativa lateral e altera&#231;&#245;es da repolariza&#231;&#227;o ventricular.</p>
    <p>A avalia&#231;&#227;o laboratorial (19 dez 2001) revelou: hemoglobina 15,5 g/dl, hemat&#243;crito 46%, colesterol total 242 mg/dl triglic&#233;rides 241 mg/dl, glicemia de jejum 107 mg/dl e creatinina 1,3 mg/dl.</p>
    <p>Foi suspenso o uso de amiodarona e prescrito atenolol.</p>
    <p>O paciente evoluiu com piora da dispneia aos esfor&#231;os. A piora foi associada ao uso de atenolol, o qual foi suspenso pelo paciente e voltou ao uso de amiodarona 200 mg/dia.</p>
    <p>Foi realizado o teste ergom&#233;trico (21 fev 2003). Na condi&#231;&#227;o basal a frequ&#234;ncia card&#237;aca foi 124 bpm e a press&#227;o arterial 134/98 mmHg; ap&#243;s 2 min e 45s de esfor&#231;o elevaram-se para 192 bpm e 158/94 mmHg. Apresentou fibrila&#231;&#227;o atrial e epis&#243;dio de taquicardia ventricular n&#227;o sustentada durante o esfor&#231;o.</p>
    <p>O eletrocardiograma de longa dura&#231;&#227;o pelo sistema Holter (21 fev 2003) revelou ritmo de fibrila&#231;&#227;o atrial, 202 extrass&#237;stoles ventriculares isoladas e um epis&#243;dio de taquicardia ventricular n&#227;o sustentada com 4 batimentos e frequ&#234;ncia de 155 bpm.</p>
    <p>O ecocardiograma (2003) revelou aumento de &#225;trios esquerdo e direito, hipertrofia septal assim&#233;trica e fra&#231;&#227;o de eje&#231;&#227;o de ventr&#237;culo esquerdo normal (<xref ref-type="table" rid="tab1">Tab. 1</xref>).</p>
    <table-wrap id="tab1">
      <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gt01.jpg"/></table-wrap>
    <p>Foram prescritos enalapril 5 mg, amiodarona 200 mg e varfarina 5 mg.</p>
    <p>Os sintomas se atenuaram; permaneceu com dispneia desencadeada por grandes esfor&#231;os e ocasionais epis&#243;dios de palpita&#231;&#245;es durante 2 anos. Sucedeu ent&#227;o r&#225;pida intensifica&#231;&#227;o da dispneia que passou a ocorrer mesmo com o paciente em repouso. Depois de um m&#234;s, n&#227;o observando melhora, procurou atendimento m&#233;dico.</p>
    <p>O exame f&#237;sico (3 jun 2004) revelou frequ&#234;ncia card&#237;aca 98 bpm, 24 incurs&#245;es respirat&#243;rias por minuto, press&#227;o arterial 140/110 mmHg, aumento da press&#227;o venosa jugular, estertores em base hemit&#243;rax esquerdo. O exame do cora&#231;&#227;o revelou batimentos arr&#237;tmicos, bulhas hipofon&#233;ticas e sopro sist&#243;lico +++/4+ em &#225;rea a&#243;rtica. O f&#237;gado foi palpado a 2 cm do rebordo costal direito e havia edema ++/4+ em membros inferiores.</p>
    <p>A radiografia de t&#243;rax revelou aumento da &#225;rea card&#237;aca de configura&#231;&#227;o arredondada.</p>
    <p>O eletrocardiograma (5 jun 2004) revelou flutter atrial, frequ&#234;ncia card&#237;aca 79 bpm, baixa voltagem do complexo QRS no plano frontal, eixo QRS desviado para direita e anteriorizado e diminui&#231;&#227;o de potenciais de ventr&#237;culo esquerdo, sugestivo de sobrecarga ventricular direita e &#225;rea eletricamente inativa parede lateral (<xref ref-type="fig" rid="a21fig01m">Figura 1</xref>).</p>
    <p content-type="asset">
      <fig id="a21fig01m">
        <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf01.jpg"/></fig>
    </p>
    <p>O ecocardiograma (3 jun 2004) revelou que as dimens&#245;es do ventr&#237;culo esquerdo e do &#225;trio esquerdo eram semelhantes &#224;s anteriormente medidas e hipertrofia do ventr&#237;culo direito e grande derrame peric&#225;rdico, sem sinais de restri&#231;&#227;o ou tamponamento card&#237;aco (<xref ref-type="table" rid="tab1">Tab. 1</xref>).</p>
    <p>Foram indicadas drenagem e bi&#243;psia peric&#225;rdica. Na interven&#231;&#227;o (5 jun 2004) houve drenagem de 450 ml de l&#237;quido citrino. O exame anatomopatol&#243;gico dos fragmentos de peric&#225;rdio examinados revelou discreta fibrose e neovasculariza&#231;&#227;o do peric&#225;rdio, sem evid&#234;ncia de c&#233;lulas neopl&#225;sicas ou infiltrado inflamat&#243;rio.</p>
    <p>O ecocardiograma de controle (15 jun 2004) revelou derrame peric&#225;rdico discreto.</p>
    <p>Houve melhora da dispneia e o paciente recebeu alta hospitalar (15 jun 2004).</p>
    <p>O mapeamento da espessura mioc&#225;rdica por ecocardiograma (4 jun 2007) revelou as seguintes medidas dos segmentos: anterior (basal 17 mm, m&#233;dio 19 mm), anterosseptal (basal 20 mm, m&#233;dio 22 mm), inferosseptal (basal 15 mm, m&#233;dio 16 mm), inferior (basal e m&#233;dio 11 mm) e inferolateral (basal 12, m&#233;dio 13 mm), anterolateral (basal 11 mm, m&#233;dio 15 mm), apical septal 14 mm, apical lateral 14 mm, calota apical 12 mm.</p>
    <p>O eletrocardiograma de alta resolu&#231;&#227;o (26 jul 2007) revelou alargamento do QRS - dura&#231;&#227;o de QRS padr&#227;o 140 ms; dura&#231;&#227;o do QRS filtrado 130 ms; dura&#231;&#227;o abaixo de 40 mV 14 ms; e aus&#234;ncia de potenciais tardios de baixa amplitude nos 40 ms finais, 61,7 mV.</p>
    <p>A dispneia aos esfor&#231;os moderados permaneceu est&#225;vel por mais 4 anos, at&#233; que em maio de 2008 progrediu at&#233; aparecer mesmo no repouso, no dec&#250;bito e surgir edema generalizado. Depois de 20 dias, como n&#227;o houvesse melhora, procurou novamente atendimento m&#233;dico (6 jun 2006).</p>
    <p>O exame f&#237;sico (6 jun 2008) revelou paciente em regular estado geral, com frequ&#234;ncia de pulso de 90 bpm, press&#227;o arterial 70/50 mmHg. A press&#227;o venosa jugular estava elevada. A semiologia pulmonar foi normal. A semiologia card&#237;aca revelou hipofonese de bulhas e n&#227;o havia sopros. O abdome era globoso e havia ascite, al&#233;m de edema escrotal e de membros inferiores ++++/4+.</p>
    <p>O ECG (6 jun 08) revelou fibrila&#231;&#227;o atrial, frequ&#234;ncia card&#237;aca 96 bpm, dura&#231;&#227;o QRS 143 ms, baixa voltagem do complexo QRS, S&#194;QRS + 130 para frente, bloqueio do ramo direito, com R puro em V1 e V2, e &#225;rea eletricamente inativa lateral (<xref ref-type="fig" rid="a21fig02m">Figura 2</xref>).</p>
    <p content-type="asset">
      <fig id="a21fig02m">
        <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf02.jpg"/></fig>
    </p>
    <p>A radiografia de t&#243;rax (6 jun 2008) revelou aumento global de &#225;rea card&#237;aca sem sinais de congest&#227;o pulmonar.</p>
    <p>Os exames laboratoriais (6 jun 08) revelaram hemoglobina 11,5 g/dl, hemat&#243;crito 34%, leuc&#243;citos 6.700/mm<sup>3</sup> (68% neutr&#243;filos, 1% eosin&#243;filos, 1% bas&#243;filos, 13% linf&#243;citos e 17% mon&#243;citos), plaquetas 161.000/mm<sup>3</sup>, ureia 67 mg/dl, creatinina 2,3 mg/dl, pot&#225;ssio 3,6 mEq/l, s&#243;dio 136 mEq/l, tempo de protrombina INR 2,7, rela&#231;&#227;o de tempos de tromboplastina ativada 1,57, creatinofosfoquinase fra&#231;&#227;o MB massa 3,73 ng/ml e troponina I 0,21 ng/ml.</p>
    <p>O ecocardiograma (11 jun 08) revelou hipocinesia do ventr&#237;culo esquerdo e direito, e de insufici&#234;ncia tric&#250;spide acentuada e derrame peric&#225;rdico moderado. (<xref ref-type="table" rid="tab1">Tab. 1</xref>).</p>
    <p>A ultrassonografia de abdome total (12 jun 08) revelou vias urin&#225;rias sem anormalidades, ectasia da veia cava inferior e hep&#225;ticas, ascite moderada, f&#237;gado com bordas rombas e textura finamente heterog&#234;nea.</p>
    <p>Os exames laboratoriais (12 jun 08) revelaram creatinina 2,94 mg/dl, ureia 110 mg/dl, pot&#225;ssio 5,9 mEq/l, s&#243;dio 134 mEq/l.</p>
    <p>A cintilografia de ventila&#231;&#227;o e de perfus&#227;o pulmonar (16 jun 08) foi considerada como de baixa probabilidade de tromboembolismo pulmonar.</p>
    <p>A cintilografia card&#237;aca com pirofosfato de tecn&#233;cio (20 jun 2008) revelou capta&#231;&#227;o discreta a moderada difusa no mioc&#225;rdio (<xref ref-type="fig" rid="fig3">Figura 3</xref> e <xref ref-type="fig" rid="fig4">4</xref>).</p>
    <fig id="fig3">
      <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf03.jpg"/></fig>
    <fig id="fig4">
      <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf04.jpg"/></fig>
    <p>A resson&#226;ncia magn&#233;tica card&#237;aca (27 jun 06) revelou dilata&#231;&#227;o biatrial acentuada; c&#226;maras ventriculares de dimens&#245;es normais; disfun&#231;&#227;o ventricular esquerda discreta por hipocinesia difusa; fun&#231;&#227;o ventricular direita normal. Havia refluxo tric&#250;spide acentuado e moderado derrame peric&#225;rdico, derrame pleural bilateral e n&#227;o havia trombos. Os achados foram considerados compat&#237;veis com amiloidose.</p>
    <p>A pesquisa de prote&#237;na de Bence Jones na urina foi negativa.</p>
    <p>Na evolu&#231;&#227;o o ecocardiograma (11 jul 08) revelou derrame peric&#225;rdico acentuado (<xref ref-type="table" rid="tab1">Tab. 1</xref>).</p>
    <p>Apesar do tratamento com uso de diur&#233;ticos e inotr&#243;picos por via intravenosa, houve piora acentuada do quadro com edema generalizado, derrame pleural e derrame peric&#225;rdico. Foi realizada outra drenagem peric&#225;rdica, al&#233;m de paracentese bilateral do t&#243;rax sem intercorr&#234;ncias (18 jul 08).</p>
    <p>O paciente apresentou tosse com expectora&#231;&#227;o purulenta. Foram identificados <italic>cocos gram</italic> positivos no l&#237;quido pleural esquerdo. Foi iniciada a antibioticoterapia com oxacilina e ceftriaxona (21 jul 08) substitu&#237;dos no dia seguinte por tazobactam e vancomicina.</p>
    <p>A ultrassonografia de abdome total (22/07/08) revelou hepatomegalia com forma e contornos normais e bordas rombas; as vias biliares intra e extra-hep&#225;ticas foram normais e havia esplenomegalia homog&#234;nea; ascite moderada. Os rins estavam normais.</p>
    <p>Os exames laboratoriais (26 jul 2008) revelaram hemoglobina 10,5 g/dl, hemat&#243;crito 33%, leuc&#243;citos 36400/mm<sup>3</sup> (3% promiel&#243;citos, 2% miel&#243;citos, 8% metamiel&#243;citos, 9% bastonetes, 63% segmentados, 2% eosin&#243;filos, 1% bas&#243;filos, 3% linf&#243;citos e 9% mon&#243;citos), plaquetas 102.000/mm<sup>3</sup>, ureia 77 mg/dl, creatinina 3 mg/dl, bilirrubinas 7,8 mg/dl (direta 6,6 mg/dl), fosfatase alcalina 107 UI/l, gama GT 215 UI/l, aspartato aminotransferase 47 UI/ml, alanina aminotransferase 45 UI/l, prote&#237;na C reativa 163 mg/l, lactato arterial 52 mg/dl, tempo de protrombina (INR) 2,1, rela&#231;&#227;o TTPA 1,5, gasimetria arterial: pH 7,20, pCO<sub>2</sub> 39,5 mmHg, pO<sub>2</sub> 75,7 mmHg, satura&#231;&#227;o de O<sub>2</sub> 92,5%, bicarbonato 14,8 mEq/l e excesso de base -12,1mEq/l.</p>
    <p>Apesar das medidas terap&#234;uticas o paciente evoluiu em choque s&#233;ptico a partir de 23 jul 2008, instalou-se fal&#234;ncia de m&#250;ltiplos &#243;rg&#227;os e faleceu em assistolia (27 jul 2008).</p>
    <p>
      <bold>Aspectos cl&#237;nicos</bold>
    </p>
    <p>O paciente, em seu quadro cl&#237;nico inicial, aos 33 anos de idade, apresentou-se com queixa de dispneia desencadeada aos esfor&#231;os. Nesse momento, havia import&#226;ncia em tentar definir a origem mais prov&#225;vel da queixa. Quando resultante de cardiopatia, a dispneia associa-se a aumento da press&#227;o capilar pulmonar, com consequente congest&#227;o intersticial secund&#225;ria. Outras potenciais causas seriam pulmonares, por altera&#231;&#245;es tireoideas, anemia, etc<sup>1,2</sup>. A presen&#231;a de aumento de &#225;rea card&#237;aca relatada na primeira radiografia de t&#243;rax aumenta, j&#225; nesse momento, a probabilidade de que a origem fosse card&#237;aca.</p>
    <p>Trata-se, portanto, de paciente com insufici&#234;ncia card&#237;aca (IC), que poderia ser decorrente de disfun&#231;&#227;o sist&#243;lica (fra&#231;&#227;o de eje&#231;&#227;o - FE - menor que 50%) ou diast&#243;lica do ventr&#237;culo esquerdo (VE) (dificuldade anormal para o enchimento do VE na di&#225;stole)<sup>3</sup>.</p>
    <p>Disfun&#231;&#227;o diast&#243;lica &#233; a causa de IC em 40 a 50% dos pacientes. Para o diagn&#243;stico de insufici&#234;ncia card&#237;aca com fra&#231;&#227;o de eje&#231;&#227;o preservada (ICFEP) e disfun&#231;&#227;o diast&#243;lica &#233; necess&#225;ria a presen&#231;a simult&#226;nea de tr&#234;s fatores: sinais ou sintomas de IC congestiva; FE de VE normal ou discretamente reduzida; e evid&#234;ncias objetivas de disfun&#231;&#227;o diast&#243;lica de VE: relaxamento e enchimento anormal do VE, distensibilidade diast&#243;lica anormal ou rigidez diast&#243;lica. As evid&#234;ncias de disfun&#231;&#227;o diast&#243;lica podem ser obtidas a partir de dados hemodin&#226;micos, n&#237;veis de pept&#237;deos natriur&#233;ticos, dados ecocardiogr&#225;ficos e do Doppler tecidual<sup>4</sup>.</p>
    <p>A evolu&#231;&#227;o com dor precordial e palpita&#231;&#245;es, ap&#243;s 2 anos, sem altera&#231;&#245;es significativas no exame f&#237;sico, com hipertrofia ventricular e fra&#231;&#227;o de eje&#231;&#227;o normal no ecocardiograma, al&#233;m de derrame peric&#225;rdico e aus&#234;ncia de coronariopatia, remete-nos &#224;s possibilidades de doen&#231;a card&#237;aca hipertensiva, miocardite acompanhada por acometimento peric&#225;rdico, cardiomiopatia hipertr&#243;fica (CMH) e s&#237;ndromes restritivas, como as doen&#231;as de dep&#243;sito.</p>
    <p>A doen&#231;a card&#237;aca hipertensiva pode ser definida como resultado da sobrecarga imposta ao VE pelo aumento da press&#227;o arterial e da resist&#234;ncia vascular perif&#233;rica total. Nesse caso, trata-se de um paciente jovem com hipertrofia ventricular esquerda (HVE) evoluindo com ICFEP. Como consequ&#234;ncia da HVE pode-se observar incid&#234;ncia aumentada de algumas arritmias, como extrass&#237;stoles ventriculares, arritmias ventriculares complexas<sup>5</sup> e fibrila&#231;&#227;o atrial (FA), o que justificaria as taquiarritmias apresentadas pelo paciente.</p>
    <p>Para o diagn&#243;stico de HVE, o eletrocardiograma (ECG) &#233; um m&#233;todo pouco sens&#237;vel, por&#233;m bastante espec&#237;fico, entretanto os achados do paciente em discuss&#227;o n&#227;o preenchem esses crit&#233;rios. J&#225; o ecocardiograma &#233; um m&#233;todo de baixo custo e &#233; considerado o m&#233;todo n&#227;o invasivo de elei&#231;&#227;o para o diagn&#243;stico de aumento de massa card&#237;aca. Poder-se-ia pensar em investiga&#231;&#227;o para hipertens&#227;o secund&#225;ria por se tratar de um paciente jovem com HVE. Por&#233;m, nesse caso, uma vez que o paciente aparentemente obteve controle press&#243;rico utilizando apenas 5 mg de enalapril, portanto com f&#225;cil controle press&#243;rico, pela evolu&#231;&#227;o apresentada e pelo fato da hipertrofia ser claramente assim&#233;trica, a hip&#243;tese de doen&#231;a card&#237;aca hipertensiva poderia ser descartada<sup>6,7</sup>.</p>
    <p>As miocardites, que s&#227;o mais frequentemente causadas por agentes virais<sup>8</sup>, possuem um amplo espectro de apresenta&#231;&#227;o cl&#237;nica, que varia desde quadros subcl&#237;nicos ou oligosintom&#225;ticos at&#233; a morte s&#250;bita card&#237;aca. A infec&#231;&#227;o por alguns agentes espec&#237;ficos pode estar associada a apresenta&#231;&#245;es menos frequentes, como o fen&#243;tipo de cardiomiopatia hipertr&#243;fica sem disfun&#231;&#227;o ventricular - inicialmente apresentado pelo caso em quest&#227;o - que pode ser causado pelo v&#237;rus da hepatite C, sendo esse de maior preval&#234;ncia em popula&#231;&#245;es de pa&#237;ses asi&#225;ticos<sup>9</sup>. Tamb&#233;m na miocardite fulminante, caracterizada por apresenta&#231;&#227;o aguda muito grave, inclusive com choque cardiog&#234;nico, observa-se, na avalia&#231;&#227;o ecocardiogr&#225;fica, um aumento da espessura septal com menor aumento dos di&#226;metros ventriculares.</p>
    <p>A presen&#231;a de arritmias associadas &#224;s altera&#231;&#245;es mioc&#225;rdicas &#233; tamb&#233;m frequente nas miocardites, necessitando muitas vezes de tratamento espec&#237;fico, e/ou sendo indicador de poss&#237;vel evolu&#231;&#227;o desfavor&#225;vel da doen&#231;a, como ocorre na miocardite de c&#233;lulas gigantes. Nesse tipo espec&#237;fico de inflama&#231;&#227;o mioc&#225;rdica, entretanto, seria esperada uma hist&#243;ria de menor dura&#231;&#227;o - diferentemente do apresentado pelo caso -, uma vez que os pacientes apresentam malmau progn&#243;stico, com sobrevida m&#233;dia de menos de 6 meses, e necessidade muito frequente de transplante card&#237;aco quando sobrevivem ao quadro agudo<sup>8</sup>. A miocardite cr&#244;nica ativa, por sua vez, caracteristicamente teria uma evolu&#231;&#227;o mais prolongada e insidiosa, em geral com manifesta&#231;&#227;o fenot&#237;pica de cardiomiopatia dilatada, chegando a &#237;ndices de mortalidade de 56% em 4 anos. Pode ainda ocorrer acometimento peric&#225;rdico associado &#224;s miocardites<sup>8</sup>.</p>
    <p>Outra hip&#243;tese para o caso s&#227;o as cardiomiopatias restritivas e infiltrativas, que se caracterizam por limita&#231;&#227;o ao enchimento ventricular e rigidez ventricular, com ventr&#237;culos normais ou discretamente dilatados e dilata&#231;&#227;o atrial importante<sup>9</sup>. A espessura ventricular &#233; normal ou aumentada, dependendo da etiologia. Os sintomas podem ser decorrentes da fal&#234;ncia do ventr&#237;culo direito (VD), que se manifesta com aumento da press&#227;o venosa jugular, edema perif&#233;rico e ascite e/ou fal&#234;ncia do VE, ocasionando dispneia e edema pulmonar<sup>10,11</sup>. A cardiomiopatia restritiva &#233; a mais rara das cardiomiopatias, sendo a amiloidose sua forma mais comum<sup>12</sup>.</p>
    <p>Como uma das causas de cardiomiopatia restritiva, a sarcoidose &#233; uma doen&#231;a granulomatosa sist&#234;mica de etiologia desconhecida, caracterizada pelo envolvimento de v&#225;rios tecidos por granulomas n&#227;o caseosos<sup>13</sup>. O envolvimento card&#237;aco prim&#225;rio &#233; infrequente e as manifesta&#231;&#245;es cl&#237;nicas aparecem em menos de 5% dos pacientes e se caracterizam por dist&#250;rbios de condu&#231;&#227;o, arritmias ventriculares, s&#237;ncope e morte s&#250;bita. O envolvimento mioc&#225;rdico direto pelos granulomas e tecido cicatricial pode manifestar-se em forma de cardiomiopatia dilatada ou restritiva, com curso progressivo<sup>14,15</sup>. O ECG &#233; inespec&#237;fico, podendo apresentar anormalidades da onda T, bloqueios ou ondas Q patol&#243;gicas. Outros achados incluem pericardite e <italic>cor pulmonale.</italic> O ecocardiograma pode revelar adelga&#231;amento das paredes ventriculares e aumento da ecogenicidade<sup>14,16</sup>. A resson&#226;ncia magn&#233;tica card&#237;aca (RMC) &#233; um m&#233;todo altamente sens&#237;vel e espec&#237;fico para o seu diagn&#243;stico. O caso apresentado mostra apenas acometimento card&#237;aco sem as demais manifesta&#231;&#245;es dessa doen&#231;a, e a RMC n&#227;o evidenciou altera&#231;&#245;es sugestivas, o que torna pouco prov&#225;vel que seja esse o diagn&#243;stico do paciente<sup>17</sup>.</p>
    <p>A doen&#231;a de Fabry &#233; um dist&#250;rbio heredit&#225;rio com heran&#231;a recessiva ligada ao cromossomo X, resultante da defici&#234;ncia da enzima lisoss&#244;mica alfa galactosidase A. Em sua forma cl&#225;ssica, caracteriza-se por envolvimento acentuado da pele, dos rins e do mioc&#225;rdio, incluindo a manifesta&#231;&#227;o de angina <italic>pectoris</italic> e infarto do mioc&#225;rdio, embora na maioria das vezes as art&#233;rias coron&#225;rias tenham aspecto angiogr&#225;fico normal. H&#225; aumento da espessura do VE, com fun&#231;&#227;o sist&#243;lica preservada e discretas, disfun&#231;&#227;o diast&#243;lica e insufici&#234;ncia mitral. A RMC &#233; adequada para diferenciar a doen&#231;a de Fabry de outras cardiomiopatias<sup>10,11</sup>. O paciente em discuss&#227;o n&#227;o apresenta manifesta&#231;&#245;es extracard&#237;acas compat&#237;veis com a doen&#231;a e a RMC &#233; sugestiva de outra doen&#231;a.</p>
    <p>A hemocromatose resulta do dep&#243;sito de ferro em tecidos parenquimatosos, como cora&#231;&#227;o, f&#237;gado, g&#244;nadas e p&#226;ncreas. Sua apresenta&#231;&#227;o cl&#225;ssica &#233; atrav&#233;s do aparecimento de insufici&#234;ncia card&#237;aca, cirrose hep&#225;tica, disfun&#231;&#227;o er&#233;til, diabetes mellitus e artrite. O envolvimento card&#237;aco leva ao padr&#227;o combinado de cardiomiopatia dilatada e cardiomiopatia restritiva com disfun&#231;&#245;es sist&#243;lica e diast&#243;lica. O ECG inclui altera&#231;&#245;es do segmento ST e da onda T e arritmias supraventriculares. O ecocardiograma revela espessamento de parede, dilata&#231;&#227;o e disfun&#231;&#227;o ventriculares. Os marcadores de cin&#233;tica do ferro mostram-se alterados<sup>10,11</sup>. A RMC com aquisi&#231;&#227;o com a t&#233;cnica T2 estrela pode fechar o diagn&#243;stico<sup>18</sup>. No paciente em quest&#227;o, n&#227;o h&#225; manifesta&#231;&#245;es extracard&#237;acas sugestivas e os exames complementares n&#227;o s&#227;o compat&#237;veis com hemocromatose.</p>
    <p>As doen&#231;as endomioc&#225;rdicas manifestam-se com fibrose endoc&#225;rdica que oblitera o &#225;pice dos ventr&#237;culos e as regi&#245;es subvalvares<sup>10,11</sup>. Como se pode observar, esse n&#227;o &#233; o padr&#227;o do paciente em discuss&#227;o.</p>
    <p>A amiloidose &#233; uma doen&#231;a de dep&#243;sito que pode ser classificada de acordo com a natureza bioqu&#237;mica da prote&#237;na amiloide em amiloidose prim&#225;ria, secund&#225;ria, senil, familiar e amiloidose dos pacientes com insufici&#234;ncia renal dial&#237;tica. Deve ser considerada como diagn&#243;stico diferencial em qualquer paciente com mais de 40 anos com insufici&#234;ncia card&#237;aca inexplic&#225;vel, s&#237;ndrome nefr&#243;tica, neuropatia perif&#233;rica ou hepatopatia. A amiloidose secund&#225;ria e a amiloidose dos pacientes renais cr&#244;nicos raramente apresentam envolvimento card&#237;aco. No ECG s&#227;o encontrados bloqueios atrioventriculares e complexos QRS de baixa voltagem, e o ECG de alta resolu&#231;&#227;o tem valor na predi&#231;&#227;o do risco de morte s&#250;bita, diferentemente do que ocorre nos casos de CMH. De forma semelhante a essa outra doen&#231;a, entretanto, a infiltra&#231;&#227;o amiloide tamb&#233;m predisp&#245;e a FA e arritmias ventriculares<sup>10,11,19,20</sup>.</p>
    <p>O ecocardiograma mostra aumento da espessura mioc&#225;rdica, que tem aspecto granuloso, dilata&#231;&#227;o de &#225;trios, derrame peric&#225;rdico, pleural ou ambos e disfun&#231;&#227;o diast&#243;lica. O derrame peric&#225;rdico n&#227;o evolui habitualmente para tamponamento card&#237;aco, e a presen&#231;a de disfun&#231;&#227;o do VD &#233; um preditor independente de mau progn&#243;stico<sup>10,11</sup>. A cintilografia com pirofosfato de tecn&#233;cio mostra capta&#231;&#227;o proporcional &#224; intensidade do dep&#243;sito amiloide<sup>11</sup>. Uma vez que esse radiois&#243;topo &#233; capaz de ligar-se ao c&#225;lcio, o exame pode estar alterado tamb&#233;m em outras situa&#231;&#245;es, como calcifica&#231;&#245;es e outras doen&#231;as de dep&#243;sito. A RMC tem alta sensibilidade e especificidade que pode variar de 75% a 94%, quando &#233; encontrado padr&#227;o caracterizado por realce global e heterog&#234;neo subendoc&#225;rdico tardio com gadol&#237;nio<sup>17,21,22</sup>, enquanto a bi&#243;psia caracteriza a subst&#226;ncia amiloide e confirma a suspeita de amiloidose.</p>
    <p>No caso em discuss&#227;o, inicialmente o diagn&#243;stico de amiloidose parece pouco prov&#225;vel pela idade do paciente e pelo ECG apresentado. Entretanto, na evolu&#231;&#227;o do caso a mudan&#231;a do padr&#227;o eletrocardiogr&#225;fico aproxima-se mais daquele comum aos casos de amiloidose (baixa voltagem), n&#227;o sendo poss&#237;vel, por&#233;m, estabelecer se isto n&#227;o teria ocorrido apenas pelo derrame peric&#225;rdico. Ademais, a pesquisa da prote&#237;na de Bence Jones foi negativa. Por outro lado, o paciente apresenta s&#237;ndrome restritiva grave e foi realizada cintilografia com pirofosfato e RMC que s&#227;o compat&#237;veis com esse diagn&#243;stico. Dessa forma, seria poss&#237;vel pensar em amiloidose card&#237;aca, em sua forma prim&#225;ria, como o diagn&#243;stico do caso apresentado.</p>
    <p>Um diagn&#243;stico diferencial da cardiomiopatia restritiva &#233; a pericardite constritiva, caracterizada por fibrose peric&#225;rdica que impede o enchimento das c&#226;maras card&#237;acas. Ocorre congest&#227;o venosa sist&#234;mica e redu&#231;&#227;o do &#237;ndice card&#237;aco. O ECG revela, normalmente, altera&#231;&#245;es inespec&#237;ficas da onda T e redu&#231;&#227;o da voltagem, al&#233;m de sinais de sobrecarga atrial esquerda ou FA. A radiografia de t&#243;rax mostra aumento atrial direito e o ecocardiograma pode revelar calcifica&#231;&#245;es peric&#225;rdicas e derrame peric&#225;rdico. Entretanto, no presente caso, foram observados aumento da espessura da parede ventricular, press&#227;o sist&#243;lica de art&#233;ria pulmonar superior a 50 mmHg e RMC sem espessamento peric&#225;rdico, sendo todas essas altera&#231;&#245;es sugestivas de s&#237;ndrome restritiva, e n&#227;o constritiva<sup>10,11</sup>.</p>
    <p>Por fim, a CMH constitui a doen&#231;a card&#237;aca gen&#233;tica de maior preval&#234;ncia<sup>23</sup> e a causa mais comum de morte s&#250;bita card&#237;aca em pessoas jovens<sup>24</sup>. &#201; caracter&#237;stico da doen&#231;a um padr&#227;o assim&#233;trico de hipertrofia, havendo mais frequentemente (em 70% a 75% dos casos) evid&#234;ncia ecocardiogr&#225;fica de hipertrofia difusa do septo ventricular e da parede anterolateral, bem como descri&#231;&#227;o de hipertrofia de ventr&#237;culo direito em alguns pacientes<sup>25</sup>. As manifesta&#231;&#245;es cl&#237;nicas podem surgir em qualquer idade, sendo mais frequente o diagn&#243;stico durante a adolesc&#234;ncia e o in&#237;cio da vida adulta.</p>
    <p>A desorganiza&#231;&#227;o da arquitetura mioc&#225;rdica induzida pela doen&#231;a, associada ao aumento da massa ventricular e a altera&#231;&#245;es presentes na microvasculatura coronariana levam a isquemia mioc&#225;rdica silenciosa, com forma&#231;&#227;o de &#225;reas de fibrose, que podem corresponder a regi&#245;es eletricamente inst&#225;veis, de onde podem se originar arritmias ventriculares. Al&#233;m disso, essas &#225;reas de fibrose, associadas &#224; hipertrofia regional (em geral, septal), podem levar a altera&#231;&#245;es no ECG, com sobrecarga atrial, por exemplo, ondas R em V1, diminui&#231;&#227;o de ondas R e surgimento de ondas Q em deriva&#231;&#245;es de parede lateral (DI, aVL, V5 e V6), altera&#231;&#245;es de repolariza&#231;&#227;o ventricular e, em caso de fibrose em parede lateral, desvio do eixo para a direita, como pode ser observado no paciente em quest&#227;o. Na evolu&#231;&#227;o da doen&#231;a, pode ainda ocorrer, de modo compat&#237;vel com esse caso, alargamento do QRS<sup>26</sup>.</p>
    <p>Os pacientes podem apresentar obstru&#231;&#227;o &#224; via de sa&#237;da do VE, que est&#225; relacionada ao desenvolvimento do quadro cl&#237;nico de insufici&#234;ncia card&#237;aca, a maior taxa de &#243;bito cardiovascular e a maior risco de morte s&#250;bita<sup>3</sup>, e que &#233; reduzida com o uso de betabloqueadores, e aumentada, entre outras situa&#231;&#245;es, na presen&#231;a de extrass&#237;stoles ventriculares (EV) e na manobra de Valsalva.</p>
    <p>O paciente em quest&#227;o apresentou piora cl&#237;nica ap&#243;s a suspens&#227;o de amiodarona e in&#237;cio do uso de atenolol. Em caso de ser CMH o diagn&#243;stico, e portanto o uso de betabloqueador ter sido corretamente indicado, a suspens&#227;o da amiodarona pode ter se associado a um aumento na frequ&#234;ncia de EV, com consequente aumento do gradiente suba&#243;rtico, podendo ter levado ao surgimento de componente obstrutivo na doen&#231;a gerando, assim, a piora do sintoma de dispneia. Outra poss&#237;vel causa da piora com a suspens&#227;o da amiodarona teria sido a maior incid&#234;ncia de arritmias parox&#237;sticas supraventriculares, como a FA, reconhecidamente associadas &#224; piora cl&#237;nica desses pacientes, com piora do progn&#243;stico<sup>23,26</sup>. Sabe-se que a incid&#234;ncia de arritmias supraventriculares, incluindo FA, por registros em Holter, pode chegar a at&#233; 30% em adultos<sup>26</sup>. A presen&#231;a de FA nessa popula&#231;&#227;o, mesmo no primeiro ou segundo epis&#243;dio parox&#237;stico, &#233; capaz de gerar forma&#231;&#227;o de trombos e fen&#244;menos cardioemb&#243;licos, fazendo com que haja indica&#231;&#227;o de anticoagula&#231;&#227;o nesses pacientes, com baixo limiar para seu in&#237;cio<sup>24,27</sup>.</p>
    <p>Dez a 15% dos pacientes evoluem com insufici&#234;ncia card&#237;aca limitante (classe funcional New York Heart Association III ou IV), e apenas 3% manifestam doen&#231;a avan&#231;ada com FE de VE menor que 50%<sup>28</sup>. Um estudo publicado em 2007 mostrou, entre 1.226 pacientes com diagn&#243;stico de CMH, preval&#234;ncia de fen&#243;tipo do tipo restritivo de 1,5%<sup>29</sup>. Os pacientes com o fen&#243;tipo estudado apresentaram mais disfun&#231;&#227;o diast&#243;lica e maior di&#226;metro atrial esquerdo, al&#233;m de menor toler&#226;ncia ao exerc&#237;cio e pior progn&#243;stico, com sobrevida de 56% em 5 anos - <italic>versus</italic> 90% naqueles sem o fen&#243;tipo do tipo restritivo (p=0,008) - tendo sido observados, em 42% dos casos, sinais de insufici&#234;ncia card&#237;aca direita, como ascite, desconforto abdominal e edema. Houve, ainda, maior tend&#234;ncia ao desenvolvimento de FA ou flutter atrial e maiores taxas de acidente vascular cerebral. Pode-se observar que, durante sua evolu&#231;&#227;o, o paciente ora relatado apresentou diversas caracter&#237;sticas compat&#237;veis com esse fen&#243;tipo da doen&#231;a.</p>
    <p>Diante da possibilidade de ocorr&#234;ncia de morte s&#250;bita, estudos pr&#233;vios definiram marcadores de risco, utilizados na estratifica&#231;&#227;o desses pacientes. Aqueles diagnosticados antes dos 14 anos de idade apresentam maior risco. Outros fatores incluem: hist&#243;ria pessoal de s&#237;ncope ou morte s&#250;bita revertida; hist&#243;ria familiar de morte s&#250;bita; hipertrofia grave (maior que 30 mm)<sup>30</sup>; presen&#231;a de taquicardia ventricular n&#227;o sustentada (TVNS) na monitoriza&#231;&#227;o por Holter; comportamento press&#243;rico anormal ao esfor&#231;o - queda da press&#227;o arterial ou aumento menor que 25 mmHg da press&#227;o sist&#243;lica<sup>26</sup>. O ECG de alta resolu&#231;&#227;o, a an&#225;lise da dispers&#227;o do intervalo QT e da variabilidade da frequ&#234;ncia card&#237;aca apresentam baixa acur&#225;cia preditiva<sup>31</sup>. No caso em quest&#227;o, o paciente apresentou, entre os fatores de risco listados, TVNS na monitoriza&#231;&#227;o por Holter, e n&#227;o teve uma curva press&#243;rica que pudesse ser avaliada no teste ergom&#233;trico, posto o baixo trabalho realizado.</p>
    <p>O quadro cl&#237;nico teve um car&#225;ter progressivo, desde o seu diagn&#243;stico, caracterizado por tr&#234;s epis&#243;dios mais importantes de descompensa&#231;&#227;o, com altera&#231;&#245;es cl&#237;nicas, eletrocardiogr&#225;ficas e ecocardiogr&#225;ficas cada vez mais significativas. Em sua &#250;ltima interna&#231;&#227;o, o paciente evoluiu com disfun&#231;&#227;o sist&#243;lica biventricular, derrame peric&#225;rdico acentuado, edema, ascite e choque cardiog&#234;nico, acompanhados por insufici&#234;ncia renal, coagulopatia e infec&#231;&#227;o pulmonar complicada com choque s&#233;ptico, culminando em &#243;bito.</p>
    <p>Considerando a idade da apresenta&#231;&#227;o inicial, as altera&#231;&#245;es cl&#237;nicas encontradas ao longo dos anos de evolu&#231;&#227;o, as altera&#231;&#245;es nos exames subsidi&#225;rios realizados e as caracter&#237;sticas de cada uma das doen&#231;as apresentadas ao longo desta discuss&#227;o, consideramos a CMH como a principal hip&#243;tese diagn&#243;stica nesse caso.</p>
    <p>Dr. Rafael Moura de Almeida e </p>
    <p> Dr. Lucas Jos&#233; Tachotti Pires</p>
    <p>
      <bold>Hip&#243;tese diagn&#243;stica</bold>
    </p>
    <p>S&#237;ndrome restritiva secund&#225;ria a cardiomiopatia hipertr&#243;fica.</p>
    <p>Dr. Rafael Moura de Almeida e </p>
    <p> Dr. Lucas Jos&#233; Tachotti Pires</p>
    <p>
      <bold>Cintilografia</bold>
    </p>
    <p>Cintilografia com 99 mTc-pirofosfato de 20 de junho de 2008 (<xref ref-type="fig" rid="fig3">Figuras 3</xref> e <xref ref-type="fig" rid="fig4">4</xref>).</p>
    <p>As imagens cintilogr&#225;ficas do t&#243;rax, realizadas 3 horas ap&#243;s a administra&#231;&#227;o endovenosa do 99 mTc-pirofosfato, obtidas nas proje&#231;&#245;es anterior e obl&#237;qua anterior esquerda de 60&#186; demonstram capta&#231;&#227;o difusa na proje&#231;&#227;o card&#237;aca de grau discreto/moderado.</p>
    <p>O 99mTc-pirofosfato liga-se ao c&#225;lcio intracelular, que se acumula nas c&#233;lulas devido a altera&#231;&#245;es do sarcolema. &#201; importante ressaltar que o mioc&#225;rdio normal n&#227;o apresenta capta&#231;&#227;o de 99mTc-pirofosfato. O exame era muito utilizado no passado para avalia&#231;&#227;o de infarto agudo do mioc&#225;rdio, onde o padr&#227;o cl&#225;ssico &#233; de capta&#231;&#227;o focal na parede acometida. A capta&#231;&#227;o difusa &#233; um achado infrequente e pouco espec&#237;fico, geralmente relacionado a doen&#231;as que acometem o cora&#231;&#227;o difusamente como amiloidose, sarcoidose, perimiocardites, endocardites ou infarto subendoc&#225;rdico. Na amiloidose o grau de capta&#231;&#227;o est&#225; relacionado com o grau de espessamento do mioc&#225;rdio, portanto com implica&#231;&#245;es progn&#243;sticas<sup>32,33</sup>. No caso em quest&#227;o, a capta&#231;&#227;o difusa em cardiomiopatia hipertr&#243;fica n&#227;o &#233; esperada, podendo estar relacionada aos achados da necropsia de infarto subendoc&#225;rdico e/ou pericardite.</p>
    <p>Dr. Jos&#233; Soares Junior, Dr. Wilson Ichiki </p>
    <p> e Dr. Wilson Andr&#233; Ichiki</p>
    <p>
      <bold>Necropsia</bold>
    </p>
    <p>&#192; abertura do saco peric&#225;rdico houve sa&#237;da de cerca de 250 ml de sangue e co&#225;gulos, observando-se pericardite fibrinosa, difusa. O cora&#231;&#227;o pesou 510 g (normal: 300-350 g) e exibia aumento do volume das quatro c&#226;maras card&#237;acas. Havia dilata&#231;&#227;o moderada do ventr&#237;culo direito e dos &#225;trios. Os ventr&#237;culos apresentavam hipertrofia moderada e sim&#233;trica, com rela&#231;&#227;o entre as espessuras do septo ventricular e da parede livre do ventr&#237;culo esquerdo = 1,2, sem obstru&#231;&#227;o cavit&#225;ria, notando-se extensas &#225;reas de fibrose no mioc&#225;rdio do ventr&#237;culo esquerdo (<xref ref-type="fig" rid="fig5">Figuras 5</xref> e <xref ref-type="fig" rid="fig6">6</xref>). O endoc&#225;rdio de ambos os ventr&#237;culos era delgado, liso e brilhante. Na aur&#237;cula direita havia um pequeno trombo misto, em organiza&#231;&#227;o. N&#227;o foram encontradas anormalidades nas valvas atrioventriculares ou ventr&#237;culo-arteriais. O estudo das art&#233;rias coron&#225;rias evidenciou trajeto intramioc&#225;rdico ("ponte mioc&#225;rdica") do 2&#186; ao 4&#186; cm do ramo interventricular esquerdo (<xref ref-type="fig" rid="fig7">Figura 7</xref>) e, &#224; histologia, havia aterosclerose coron&#225;ria leve, com obstru&#231;&#227;o m&#225;xima de 30% da luz das art&#233;rias coron&#225;rias principais.</p>
    <fig id="fig5">
      <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf05.jpg"/></fig>
    <fig id="fig6">
      <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf06.jpg"/></fig>
    <fig id="fig7">
      <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf07.jpg"/></fig>
    <p>Cortes histol&#243;gicos dos ventr&#237;culos mostraram hipertrofia mioc&#225;rdica difusa, desarranjo espacial de cardiomi&#243;citos e de feixes de fibras card&#237;acas em mais de 20% das &#225;reas amostradas, fibrose intersticial difusa desde a regi&#227;o subendoc&#225;rdica at&#233; a subepic&#225;rdica, e espessamento da parede das art&#233;rias coron&#225;rias intramurais devido &#224; prolifera&#231;&#227;o mediointimal de c&#233;lulas musculares lisas (<xref ref-type="fig" rid="a21fig08m">figura 8</xref>). Embora presentes em ambos os ventr&#237;culos, essas altera&#231;&#245;es eram mais acentuadas no septo ventricular e na parede livre do ventr&#237;culo esquerdo. As pesquisas histoqu&#237;micas de subst&#226;ncia amil&#243;ide e de glicog&#234;nio no mioc&#225;rdio resultaram negativas. Diante dos achados anatomopatol&#243;gicos da necropsia, fez-se o diagn&#243;stico de cardiomiopatia hipertr&#243;fica, forma restritiva, sem obstru&#231;&#227;o da via de sa&#237;da. Observou-se, ainda, congest&#227;o passiva cr&#244;nica em pulm&#245;es, f&#237;gado e ba&#231;o e edema generalizado de tecido subcut&#226;neo, consequentes &#224; insufici&#234;ncia card&#237;aca congestiva.</p>
    <p content-type="asset">
      <fig id="a21fig08m">
        <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf08.jpg"/></fig>
    </p>
    <p>Nos demais &#243;rg&#227;os foram encontradas altera&#231;&#245;es secund&#225;rias ao choque, representadas por dano alveolar difuso e hemorragia intralveolar nos pulm&#245;es, necrose tubular aguda nos rins, necrose hep&#225;tica centrilobular e infartos subendoc&#225;rdicos recentes, pequenos e multifocais. Nos pulm&#245;es havia &#225;reas localizadas de broncopneumonia em fase inicial. Por&#233;m, n&#227;o foram observadas altera&#231;&#245;es morfol&#243;gicas sugestivas de infec&#231;&#227;o em outros &#243;rg&#227;os. A presen&#231;a de sangue e co&#225;gulos no saco peric&#225;rdico pareceu ser mais um evento final, resultado das manobras de ressuscita&#231;&#227;o.</p>
    <p>A causa do &#243;bito foi fal&#234;ncia de m&#250;ltiplos &#243;rg&#227;os decorrente de choque, predominantemente cardiog&#234;nico e agravado pela infec&#231;&#227;o pulmonar.</p>
    <p>
      <bold>L&#233;a Maria Macruz Ferreira Demarchi</bold>
    </p>
    <p>
      <bold>Diagn&#243;sticos anatomopatol&#243;gicos</bold>
    </p>
    <p>1) Cardiomiopatia hipertr&#243;fica sim&#233;trica, n&#227;o obstrutiva; 2) Insufici&#234;ncia card&#237;aca congestiva; 3) Choque misto (cardiog&#234;nico/infeccioso); 4) Fal&#234;ncia de m&#250;ltiplos &#243;rg&#227;os.</p>
    <p>
      <bold>L&#233;a Maria Macruz Ferreira Demarchi</bold>
    </p>
    <p>
      <bold>Coment&#225;rio</bold>
    </p>
    <p>A cardiomiopatia hipertr&#243;fica (CMH) &#233; definida como cardiomiopatia prim&#225;ria gen&#233;tica, caracterizada morfologicamente por hipertrofia n&#227;o dilatada do ventr&#237;culo esquerdo, na aus&#234;ncia de outra doen&#231;a sist&#234;mica ou card&#237;aca capaz de causar tal altera&#231;&#227;o ventricular, como por exemplo, a hipertens&#227;o arterial sist&#234;mica e a estenose de valva a&#243;rtica<sup>34</sup>.</p>
    <p>Tem espectro cl&#237;nico abrangente, exibindo grande variabilidade morfol&#243;gica, de sintomas e risco de complica&#231;&#245;es como morte s&#250;bita e insufici&#234;ncia card&#237;aca<sup>35</sup>.</p>
    <p>As principais caracter&#237;sticas anat&#244;micas da CMH foram obtidas a partir de dados de observa&#231;&#227;o de necropsias e s&#227;o assim definidas<sup>34</sup>: hipertrofia mioc&#225;rdica, desarranjo espacial de cardiomi&#243;citos, art&#233;rias coron&#225;rias intramurais com altera&#231;&#245;es obstrutivas e fibrose mioc&#225;rdica.</p>
    <p>A hipertrofia mioc&#225;rdica pode ser assim&#233;trica ou sim&#233;trica. A forma de apresenta&#231;&#227;o mais comum &#233; a assim&#233;trica, caracterizada por hipertrofia mais acentuada do septo ventricular, sendo que a rela&#231;&#227;o entre as espessuras do septo ventricular/parede lateral do ventr&#237;culo esquerdo deve ser igual ou maior que 1,3<sup>36</sup>. Quando localizada na por&#231;&#227;o basal do septo ventricular, a hipertrofia causa obstru&#231;&#227;o da via de sa&#237;da do ventr&#237;culo esquerdo e, consequentemente, h&#225; espessamento da c&#250;spide anterior mitral e fibrose endoc&#225;rdica septal suba&#243;rtica. Devido ao atrito constante entre o folheto valvar e o endoc&#225;rdio septal, a fibrose endoc&#225;rdica pode adquirir o formato de imagem em espelho da c&#250;spide anterior mitral. A forma sim&#233;trica caracteriza-se por hipertrofia conc&#234;ntrica do ventr&#237;culo esquerdo, sem obstru&#231;&#227;o da via de sa&#237;da ventricular.</p>
    <p>Na CMH, o desarranjo espacial de cardiomi&#243;citos deve estar presente em mais de 20% das &#225;reas histologicamente amostradas<sup>37</sup> e caracteriza-se por conex&#245;es intercelulares m&#250;ltiplas e ca&#243;ticas, sob a forma de &#226;ngulos retos e obl&#237;quos<sup>34</sup>. Pode ser encontrado em qualquer parede de ambos os ventr&#237;culos e, mais frequentemente, ocupa grandes por&#231;&#245;es do ventr&#237;culo esquerdo. &#193;reas extensas de desarranjo s&#227;o descritas em pacientes jovens que morreram em consequ&#234;ncia da doen&#231;a<sup>34</sup>.</p>
    <p>As art&#233;rias coron&#225;rias intramurais apresentam altera&#231;&#245;es obstrutivas caracterizadas por espessamento de parede e estreitamento luminal, devido ao aumento de deposi&#231;&#227;o de col&#225;geno nas t&#250;nicas &#237;ntima e m&#233;dia. Tais altera&#231;&#245;es, associadas &#224; despropor&#231;&#227;o entre a hipertrofia da massa ventricular e a circula&#231;&#227;o coron&#225;ria, resultam em isquemia mioc&#225;rdica e consequente fibrose, que pode ser focal ou transmural<sup>34</sup>.</p>
    <p>Outro achado frequente na CMH &#233; o trajeto intramural ou "ponte mioc&#225;rdica" do ramo interventricular anterior da art&#233;ria coron&#225;ria esquerda, que tamb&#233;m foi observado nesse doente, mas seu significado fisiopatol&#243;gico ainda n&#227;o est&#225; totalmente esclarecido<sup>38</sup>.</p>
    <p>A contribui&#231;&#227;o da bi&#243;psia endomioc&#225;rdica (BEM) para o diagn&#243;stico da cardiomiopatia hipertr&#243;fica &#233; bastante limitada e, no caso em discuss&#227;o, n&#227;o mostrou desarranjo mioc&#225;rdico, apenas hipertrofia de cardiomi&#243;citos. Na CMH, as &#225;reas de desarranjo localizam-se frequentemente em regi&#245;es mais profundas da parede ventricular, distantes da regi&#227;o subendoc&#225;rdica, e, portanto, fora do alcance do bi&#243;tomo. Por&#233;m, a BEM se mostra &#250;til para o diagn&#243;stico diferencial entre outras causas de hipertrofia ventricular, como amiloidose, doen&#231;a de Pompe e, at&#233; mesmo, neoplasias<sup>37,39</sup>.</p>
    <p>Os achados anatomopatol&#243;gicos obtidos pela necropsia, associados aos dados cl&#237;nicos e de exames complementares, foram fundamentais para o diagn&#243;stico de CMH nesse doente.</p>
    <p>
      <bold>Dra. L&#233;a Maria Macruz Ferreira Demarchi</bold>
    </p>
    <p>
      <fn id="end" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Vera D. Aiello </p>
        <p> InCor </p>
        <p> Av. Dr. En&#233;as de Carvalho Aguiar, 44 </p>
        <p> 05403-000 - S&#227;o Paulo, SP </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="anpvera@incor.usp.br">anpvera@incor.usp.br</email>
        </p>
      </fn>
    </p>
    <p><bold>Editor da Se&#231;&#227;o:</bold> Alfredo Jos&#233; Mansur (<email xlink:href="ajmansur@incor.usp.br">ajmansur@incor.usp.br</email>) </p>
    <p><bold>Editores Associados:</bold> Desid&#233;rio Favarato (<email xlink:href="dclfavarato@incor.usp.br">dclfavarato@incor.usp.br</email>); Vera Demarchi Aiello (<email xlink:href="anpvera@incor.usp.br">anpvera@incor.usp.br</email>)</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Romano MM, Maciel BC. Hist&#243;ria cl&#237;nica. In: Serrano Jr CV, Timerman A, Stefanini E, editores. Tratado de cardiologia SOCESP. 2&#350; ed. Barueri (SP): Manole; 2009. p. 211-22.</mixed-citation>
        <element-citation publication-type="book">
          <source>Tratado de cardiologia SOCESP</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>211</fpage>
          <lpage>22</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Romano</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Maciel</surname>
              <given-names>BC.</given-names>
            </name>
            <name>
              <surname>Serrano Jr</surname>
              <given-names>CV</given-names>
            </name>
            <name>
              <surname>Timerman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Stefanini</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Ingram Jr RH, Braunwald E. Dyspnea and pulmonary edema. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison's principles of internal medicine. New York: McGraw-Hill; 2001. p. 199-203.</mixed-citation>
        <element-citation publication-type="book">
          <source>Harrison's principles of internal medicine</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>199</fpage>
          <lpage>203</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Ingram Jr</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Braunwald</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Braunwald</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Fauci</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Kasper</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Hauser</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Longo</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Jameson</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003; 348 (4): 295-303.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>295</fpage>
          <lpage>303</lpage>
          <issue>4</issue>
          <volume>348</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Maron</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Olivotto</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Betocchi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Casey</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Lesser</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Losi</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Bocchi EA, Marcondes-Braga FG, Ayub-Ferreira SM, Rohde LE, Oliveira WA, Almeida DR, et al / Sociedade Brasileira de Cardiologia. III Diretriz brasileira de insufici&#234;ncia card&#237;aca cr&#244;nica. Arq Bras Cardiol. 2009; 92 (6 supl.1): 1-71.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>III Diretriz brasileira de insufici&#234;ncia card&#237;aca cr&#244;nica</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>1</fpage>
          <lpage>71</lpage>
          <issue>6</issue>
          <volume>92</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Marcondes-Braga</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Ayub-Ferreira</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Rohde</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Messerli FH. Left ventricular hypertrophy, arterial hypertension and sudden death. J Hypertens. 1990; 8 (Suppl. 7): 181-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left ventricular hypertrophy, arterial hypertension and sudden death</article-title>
          <source>J Hypertens</source>
          <date>
            <year>1990</year>
          </date>
          <fpage>181</fpage>
          <lpage>6</lpage>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Messerli</surname>
              <given-names>FH.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. P&#243;voa RMS, Bombig MTN. Cardiopatia hipertensiva. In: Serrano Jr CV, Timerman A, Stefanini E, editores. Tratado de cardiologia SOCESP. 2&#350; ed. Barueri (SP): Manole; 2009. p. 777-88.</mixed-citation>
        <element-citation publication-type="book">
          <source>Tratado de cardiologia SOCESP</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>777</fpage>
          <lpage>88</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>P&#243;voa</surname>
              <given-names>RMS</given-names>
            </name>
            <name>
              <surname>Bombig</surname>
              <given-names>MTN.</given-names>
            </name>
            <name>
              <surname>Serrano Jr</surname>
              <given-names>CV</given-names>
            </name>
            <name>
              <surname>Timerman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Stefanini</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Victor RG, Kaplan NM. Sysmic hypertension: mechanisms and diagnosis. In: Libby P, Bonow RO, Mann LD, Zipes PD, editors. Braunwald's heart disease: a textbook of cardiovascular medicine. 8th ed. Philadelphia: Elsevier Saunders; 2008. p. 1027-48.</mixed-citation>
        <element-citation publication-type="book">
          <source>Braunwald's heart disease: a textbook of cardiovascular medicine</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>1027</fpage>
          <lpage>48</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Victor</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Kaplan</surname>
              <given-names>NM.</given-names>
            </name>
            <name>
              <surname>Libby</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bonow</surname>
              <given-names>RO</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Zipes</surname>
              <given-names>PD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Cardoso JN, Pereira-Barreto AC. Miocardites. In: Serrano Jr CV, Timerman A, Stefanini E, editores. Tratado de cardiologia SOCESP. 2&#350; ed. Barueri (SP): Manole; 2009. p. 1146-52.</mixed-citation>
        <element-citation publication-type="book">
          <source>Tratado de cardiologia SOCESP</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>1146</fpage>
          <lpage>52</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Cardoso</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Pereira-Barreto</surname>
              <given-names>AC.</given-names>
            </name>
            <name>
              <surname>Serrano Jr</surname>
              <given-names>CV</given-names>
            </name>
            <name>
              <surname>Timerman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Stefanini</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Liu PP, Schultheiss HP. Myocarditis. In: Libby P, Bonow RO, Mann DL, Zipes DP, editors. Braunwald's heart disease. 8th ed. Philadelphia: Elsevier Saunders; 2008. p. 1775-92.</mixed-citation>
        <element-citation publication-type="book">
          <source>Braunwald's heart disease</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>1775</fpage>
          <lpage>92</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Schultheiss</surname>
              <given-names>HP.</given-names>
            </name>
            <name>
              <surname>Libby</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bonow</surname>
              <given-names>RO</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Zipes</surname>
              <given-names>DP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Gimenes VML. Cardiomiopatias restritivas e infiltrativas. In: Serrano Jr CV, Timerman A, Stefanini E, editores. Tratado de cardiologia SOCESP. 2&#350; ed. Barueri (SP): Manole; 2009. p. 1208-21.</mixed-citation>
        <element-citation publication-type="book">
          <source>Tratado de cardiologia SOCESP</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>1208</fpage>
          <lpage>21</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Gimenes</surname>
              <given-names>VML.</given-names>
            </name>
            <name>
              <surname>Serrano Jr</surname>
              <given-names>CV</given-names>
            </name>
            <name>
              <surname>Timerman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Stefanini</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11.  Hare JM. The dilated, restrictive and infiltrative cardiomyopathies. In: Libby P, Bonow RO, Mann LD, Zipes PD, editors. Braunwald's heart disease: a textbook of cardiovascular medicine. 8th ed. Philadelphia: Elsevier Saunders; 2008. p. 1739-62.</mixed-citation>
        <element-citation publication-type="book">
          <source>Braunwald's heart disease: a textbook of cardiovascular medicine</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>1739</fpage>
          <lpage>62</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Hare</surname>
              <given-names>JM.</given-names>
            </name>
            <name>
              <surname>Libby</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bonow</surname>
              <given-names>RO</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Zipes</surname>
              <given-names>PD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12.  Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Engl J Med. 1997; 336 (4): 267-77.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Restrictive cardiomyopathy</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>267</fpage>
          <lpage>77</lpage>
          <issue>4</issue>
          <volume>336</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kushwaha</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Fallon</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Fuster</surname>
              <given-names>V.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Sharma OP. Diagnosis of cardiac sarcoidosis: an imperfect science, a hesitant art. Chest. 2003; 123 (1): 18-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Diagnosis of cardiac sarcoidosis: an imperfect science, a hesitant art</article-title>
          <source>Chest</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>18</fpage>
          <lpage>9</lpage>
          <issue>1</issue>
          <volume>123</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sharma</surname>
              <given-names>OP.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Yazaki Y, Isobe M, Hiramitsu S, Hiroe M, Omichi C, Nakano T, et al. Comparison of clinical features and prognosis of cardiac sarcoidosis and idiopathic dilated cardiomyopathy. Am J Cardiol. 1998; 82 (4): 537-40.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Comparison of clinical features and prognosis of cardiac sarcoidosis and idiopathic dilated cardiomyopathy</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>537</fpage>
          <lpage>40</lpage>
          <issue>4</issue>
          <volume>82</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yazaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Isobe</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hiramitsu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hiroe</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Omichi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Nakano</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Pisani B, Taylor DO, Mason JW. Inflammatory myocardial diseases and cardiomyopathies. Am J Med. 1997; 102 (5): 459-69.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Inflammatory myocardial diseases and cardiomyopathies</article-title>
          <source>Am J Med</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>459</fpage>
          <lpage>69</lpage>
          <issue>5</issue>
          <volume>102</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pisani</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>DO</given-names>
            </name>
            <name>
              <surname>Mason</surname>
              <given-names>JW.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Shimada T, Shimada K, Sakane T, Ochiai K, Tsukihashi H, Fukui M, et al. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med. 2001; 110 (7): 520-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging</article-title>
          <source>Am J Med</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>520</fpage>
          <lpage>7</lpage>
          <issue>7</issue>
          <volume>110</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Shimada</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shimada</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sakane</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ochiai</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tsukihashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fukui</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Dassen WR, Gorgels AP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005; 45 (10): 1683-90.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1683</fpage>
          <lpage>90</lpage>
          <issue>10</issue>
          <volume>45</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Smedema</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Snoep</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>van Kroonenburgh</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>van Geuns</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Dassen</surname>
              <given-names>WR</given-names>
            </name>
            <name>
              <surname>Gorgels</surname>
              <given-names>AP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18.  Schmidt A, Rochitte CE. Resson&#226;ncia magn&#233;tica card&#237;aca. In: Serrano Jr CV, Timerman A, Stefanini E, editores. Tratado de cardiologia SOCESP. 2&#350; ed. Barueri (SP): Manole; 2009. p. 437-52.</mixed-citation>
        <element-citation publication-type="book">
          <source>Tratado de cardiologia SOCESP</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>437</fpage>
          <lpage>52</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Schmidt</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rochitte</surname>
              <given-names>CE.</given-names>
            </name>
            <name>
              <surname>Serrano Jr</surname>
              <given-names>CV</given-names>
            </name>
            <name>
              <surname>Timerman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Stefanini</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol. 2007; 50 (22): 2101-10.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Evaluation and management of the cardiac amyloidosis</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>2101</fpage>
          <lpage>10</lpage>
          <issue>22</issue>
          <volume>50</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Selvanayagam</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Hawkins</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Myerson</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Neubauer</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20.  Falk RH. Diagnosis and management of the cardiac amyloidoses, Circulation. 2005; 112: 2047-60.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Diagnosis and management of the cardiac amyloidoses</article-title>
          <source>Circulation</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>2047</fpage>
          <lpage>60</lpage>
          <volume>112</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Falk</surname>
              <given-names>RH.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Kwong RY, Falk RH. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005; 111 (2): 122-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiovascular magnetic resonance in cardiac amyloidosis</article-title>
          <source>Circulation</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>122</fpage>
          <lpage>4</lpage>
          <issue>2</issue>
          <volume>111</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kwong</surname>
              <given-names>RY</given-names>
            </name>
            <name>
              <surname>Falk</surname>
              <given-names>RH.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol. 2008; 51 (10): 1022-30.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>1022</fpage>
          <lpage>30</lpage>
          <issue>10</issue>
          <volume>51</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Vogelsberg</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mahrholdt</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Deluigi</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Yilmaz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kispert</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Greulich</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Bregagnollo EA, Carvalho FC. Cardiomiopatia hipertr&#243;fica. In: Serrano Jr CV, Timerman A, Stefanini E, editores. Tratado de cardiologia SOCESP. 2&#350; ed. Barueri (SP): Manole; 2009. p. 1181-207.</mixed-citation>
        <element-citation publication-type="book">
          <source>Tratado de cardiologia SOCESP</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>1181</fpage>
          <lpage>207</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Bregagnollo</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>FC.</given-names>
            </name>
            <name>
              <surname>Serrano Jr</surname>
              <given-names>CV</given-names>
            </name>
            <name>
              <surname>Timerman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Stefanini</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Maron BJ. Hypertrophic cardiomyopathy. In: Libby P, Bonow RO, Mann DL, Zipes DP, editors. Braunwald's heart disease. 8th ed. Philadelphia: Elsevier Saunders; 2008. p. 1763-74.</mixed-citation>
        <element-citation publication-type="book">
          <source>Braunwald's heart disease</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>1763</fpage>
          <lpage>74</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Maron</surname>
              <given-names>BJ.</given-names>
            </name>
            <name>
              <surname>Libby</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bonow</surname>
              <given-names>RO</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Zipes</surname>
              <given-names>DP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Connolly HM, Oh JK. Echocardiography. In: Libby P, Bonow RO, Mann DL, Zipes DP, editors. Braunwald's heart disease. 8th ed. Philadelphia: Elsevier Saunders; 2008. p. 227-325.</mixed-citation>
        <element-citation publication-type="book">
          <source>Braunwald's heart disease</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>227</fpage>
          <lpage>325</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Connolly</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Oh</surname>
              <given-names>JK.</given-names>
            </name>
            <name>
              <surname>Libby</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bonow</surname>
              <given-names>RO</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Zipes</surname>
              <given-names>DP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. McKenna WJ, Behr ER. Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart. 2002; 87 (2): 169-76.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death</article-title>
          <source>Heart</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>169</fpage>
          <lpage>76</lpage>
          <issue>2</issue>
          <volume>87</volume>
          <person-group person-group-type="author">
            <name>
              <surname>McKenna</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Behr</surname>
              <given-names>ER.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J. 2003; 24 (21): 1965-91.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1965</fpage>
          <lpage>91</lpage>
          <issue>21</issue>
          <volume>24</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Maron</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>McKenna</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Danielson</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>Kappenberger</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Kuhn</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Seidman</surname>
              <given-names>CE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114 (3): 216-25.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy</article-title>
          <source>Circulation</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>216</fpage>
          <lpage>25</lpage>
          <issue>3</issue>
          <volume>114</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Harris</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Spirito</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Maron</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Zenovich</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Formisano</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lesser</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Kubo T, Gimeno JR, Bahl A, Steffensen U, Steffensen M, Osman E, et al. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J Am Coll Cardiol. 2007;49 (25): 2419-26.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>2419</fpage>
          <lpage>26</lpage>
          <issue>25</issue>
          <volume>49</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kubo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gimeno</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Bahl</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Steffensen</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Steffensen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Osman</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000; 342 (24): 1778-85.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>1778</fpage>
          <lpage>85</lpage>
          <issue>24</issue>
          <volume>342</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Spirito</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bellone</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Bernabo</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bruzzi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Maron</surname>
              <given-names>BJ.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Piva e Mattos B. Estratifica&#231;&#227;o de risco para morte s&#250;bita na cardiomiopatia hipertr&#243;fica: bases gen&#233;ticas e cl&#237;nicas. Arq Bras Cardiol. 2006; 87 (3): 391-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Estratifica&#231;&#227;o de risco para morte s&#250;bita na cardiomiopatia hipertr&#243;fica: bases gen&#233;ticas e cl&#237;nicas</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>391</fpage>
          <lpage>9</lpage>
          <issue>3</issue>
          <volume>87</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Piva e Mattos</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. Taki J, Taki S, Ichiyanagi K, Akashi Y, Hisada K. Acute subendocardial infarction with diffuse intense Tc-99m PYP uptake and minimal Tl-201 abnormality. Clin Nucl Med. 1992; 17 (8): 643-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Acute subendocardial infarction with diffuse intense Tc-99m PYP uptake and minimal Tl-201 abnormality</article-title>
          <source>Clin Nucl Med</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>643</fpage>
          <lpage>5</lpage>
          <issue>8</issue>
          <volume>17</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Taki</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Taki</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ichiyanagi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Akashi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hisada</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Yazaki Y, Isobe M, Hayasaka M, Tanaka M, Fujii T, Sekiguchi M. Cardiac sarcoidosis mimicking hypertrophic cardiomyopathy: clinical utility of radionuclide imaging for differential diagnosis. Jpn Circ J. 1998; 62 (6): 465-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac sarcoidosis mimicking hypertrophic cardiomyopathy: clinical utility of radionuclide imaging for differential diagnosis</article-title>
          <source>Jpn Circ J</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>465</fpage>
          <lpage>8</lpage>
          <issue>6</issue>
          <volume>62</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yazaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Isobe</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hayasaka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fujii</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sekiguchi</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006; 113 (14): 1807-16.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention</article-title>
          <source>Circulation</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>1807</fpage>
          <lpage>16</lpage>
          <issue>14</issue>
          <volume>113</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Maron</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Towbin</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Thiene</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Antzelevitch</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Corrado</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Arnett</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B35">
        <mixed-citation>35. Varnava AM, Elliott PM, Mahon N, Davies MJ, McKenna WJ. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol. 2001; 88 (3): 275-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>275</fpage>
          <lpage>9</lpage>
          <issue>3</issue>
          <volume>88</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Varnava</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Elliott</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Mahon</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>McKenna</surname>
              <given-names>WJ.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B36">
        <mixed-citation>36. Maron BJ, Anan TJ, Roberts WC. Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy. Circulation. 1981; 63 (4): 882-94.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy</article-title>
          <source>Circulation</source>
          <date>
            <year>1981</year>
          </date>
          <fpage>882</fpage>
          <lpage>94</lpage>
          <issue>4</issue>
          <volume>63</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Maron</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Anan</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>WC.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B37">
        <mixed-citation>37. Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy: an introduction to pathology and pathogenesis. Br Heart J. 1994; 72 (6 Suppl.): S2-3.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Hypertrophic cardiomyopathy: an introduction to pathology and pathogenesis</article-title>
          <source>Br Heart J</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>S2</fpage>
          <lpage>3</lpage>
          <volume>72</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Davies</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>McKenna</surname>
              <given-names>WJ.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B38">
        <mixed-citation>38. Basso C, Thiene G, Mackey-Bojack S, Frigo AC, Corrado D, Maron BJ. Myocardial bridging, a frequent component of the hypertrophic cardiomyopathy phenotype, lacks systematic association with sudden cardiac death. Eur Heart J. 2009; 30 (13): 1627-34.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Myocardial bridging, a frequent component of the hypertrophic cardiomyopathy phenotype, lacks systematic association with sudden cardiac death</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>1627</fpage>
          <lpage>34</lpage>
          <issue>13</issue>
          <volume>30</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Basso</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Thiene</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mackey-Bojack</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Frigo</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Corrado</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Maron</surname>
              <given-names>BJ.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B39">
        <mixed-citation>39. Edwards WD. Cardiomyopathies. Hum Pathol. 1987; 18 (6): 625-35.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiomyopathies</article-title>
          <source>Hum Pathol</source>
          <date>
            <year>1987</year>
          </date>
          <fpage>625</fpage>
          <lpage>35</lpage>
          <issue>6</issue>
          <volume>18</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Edwards</surname>
              <given-names>WD.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Caso 5/2010: hombre de 41 a&#241;os de edad portador de hipertrofia mioc&#225;rdica con evoluci&#243;n a insuficiencia card&#237;aca congestiva</article-title>
      </title-group>
      <kwd-group xml:lang="es">
        <kwd>Insuficiencia card&#237;aca</kwd>
        <kwd>hipertrofia ventricular izquierda</kwd>
        <kwd>ipertensi&#243;n</kwd>
        <kwd>fibrilaci&#243;n atrial</kwd>
        <kwd>amiloidosis</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>CORRELACI&#211;N ANATOMOCL&#205;NICA</bold>
      </p>
      <p>
        <fn id="top-body2">
          <label>
            <bold>Caso 5/2010 - hombre de 41 a&#241;os de edad portador de hipertrofia mioc&#225;rdica con evoluci&#243;n a insuficiencia card&#237;aca congestiva</bold>
          </label>
          <p>
            <bold>Rafael Moura de Almeida; Lucas Jos&#233; Tachotti Pires; Jos&#233; Soares J&#250;nior; Wilson Ichiki; Wilson Andr&#233; Ichiki; L&#233;a Maria Macruz Ferreira Demarchi</bold>
          </p>
        </fn>
      </p>
      <p>Instituto do Cora&#231;&#227;o (InCor) HC-FMUSP, S&#227;o Paulo, SP - Brasil</p>
      <p>Correspondencia</p>
      <p><bold>Palabras-clave:</bold> Insuficiencia card&#237;aca; hipertrofia ventricular izquierda; ipertensi&#243;n; fibrilaci&#243;n atrial; amiloidosis.</p>
      <p>Hombre de 41 a&#241;os, natural y procedente de la ciudad de S&#227;o Paulo, procur&#243; atenci&#243;n debido a disnea r&#225;pidamente progresiva y edema generalizado.</p>
      <p>El paciente sab&#237;a que era portador de hipertensi&#243;n arterial y de hipertrofia de ventr&#237;culo izquierdo.</p>
      <p>El paciente era asintom&#225;tico hasta los 33 a&#241;os de edad cuando comenz&#243; a presentar disnea a los esfuerzos. Procur&#243; atenci&#243;n m&#233;dica en la ocasi&#243;n y fue diagnosticado aumento del &#225;rea card&#237;aca. El cuadro se mantuvo estable hasta los 35 a&#241;os (mayo 2001) cuando present&#243; episodio de palpitaciones taquic&#225;rdicas y dolor precordial. Procur&#243; atenci&#243;n m&#233;dica y fue hecho el diagn&#243;stico de flutter atrial. El ecocardiograma (13 set 2001) revel&#243; hipertrofia moderada de ventr&#237;culo izquierdo y derrame peric&#225;rdico moderado; la cineangiocoronariograf&#237;a (18 oct 2001) no revel&#243; lesiones obstructivas en las arterias coronarias. Recibi&#243; prescripci&#243;n de amiodarona y fue encaminado a este Hospital.</p>
      <p>El examen f&#237;sico (13 dic 2001) revel&#243; frecuencia card&#237;aca 68 lpm, presi&#243;n arterial de 140/95 mm Hg. Lo restante del examen f&#237;sico no revel&#243; otras alteraciones o hallazgos diagn&#243;sticos.</p>
      <p>El electrocardiograma (18 dic 2001) revel&#243; ritmo sinusal, frecuencia 78 lpm, duraci&#243;n del PR 157 ms, del QRS 108 ms, del QT 414 ms, SAQRS + 130&#186; para atr&#225;s. El an&#225;lisis morfol&#243;gico revel&#243; onda P de amplitud aumentada, QS en derivaciones I, aVL y onda Q en V6. Fueron hechos los diagn&#243;sticos de sobrecarga atrial derecha, &#225;rea el&#233;ctricamente inactiva lateral y alteraciones de la repolarizaci&#243;n ventricular.</p>
      <p>La evaluaci&#243;n de laboratorio (19 dic 2001) revel&#243;: hemoglobina 15,5 g/dL, hematocrito 46%, colesterol total 242 mg/dL triglic&#233;ridos 241 mg/dL, glicemia de ayuno 107 mg/dL y creatinina 1,3 mg/dL.</p>
      <p>Fue suspendido el uso de amiodarona y prescripto atenolol.</p>
      <p>El paciente evolucion&#243; con empeoramiento de la disne a los esfuerzos. El empeoramiento fue asociado al uso de atenolol, el cual fue suspendido por el paciente y volvi&#243; al uso de amiodarona 200 mg/d&#237;a.</p>
      <p>Fue realizado el test ergom&#233;trico (21 feb 2003). En condici&#243;n basal la frecuencia card&#237;aca fue 124 lpm y la presi&#243;n arterial 134/98 mm Hg; despu&#233;s de 2 min y 45s de esfuerzo se elevaron a 192 lpm y 158/94 mm Hg. Present&#243; fibrilaci&#243;n atrial y episodio de taquicardia ventricular no sostenida durante el esfuerzo.</p>
      <p>El electrocardiograma de larga duraci&#243;n por el sistema Holter (21 feb 2003) revel&#243; ritmo de fibrilaci&#243;n atrial, 202 extras&#237;stoles ventriculares aisladas y un episodio de taquicardia ventricular no sustentada con 4 latidos y frecuencia de 155 lpm.</p>
      <p>El ecocardiograma (2003) revel&#243; aumento de atrios izquierdo y derecho, hipertrofia septal asim&#233;trica y fracci&#243;n de eyecci&#243;n de ventr&#237;culo izquierdo normal. (<xref ref-type="table" rid="tab1-body2">Tab. 1</xref>)</p>
      <table-wrap id="tab1-body2">
        <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gt01-es.jpg"/></table-wrap>
      <p>Fueron prescriptos enalapril 5 mg, amiodarona 200 mg y varfarina 5 mg.</p>
      <p>Los s&#237;ntomas se atenuaron; permaneci&#243; con disnea desencadenada por grandes esfuerzos y ocasionales episodios de palpitaciones durante 2 a&#241;os. Sucedi&#243; entonces r&#225;pida intensificaci&#243;n de la disnea que comenz&#243; a ocurrir aun con el paciente en reposo. Despu&#233;s de un mes, no observando mejora, procur&#243; atenci&#243;n m&#233;dica.</p>
      <p>El examen f&#237;sico (3 jun 2004) revel&#243; frecuencia card&#237;aca 98 lpm, 24 incursiones respiratorias por minuto, presi&#243;n arterial 140/110 mm Hg, aumento de la presi&#243;n venosa yugular, estertores en base hemit&#243;rax izquierdo. El examen del coraz&#243;n revel&#243; latidos arr&#237;tmicos, ruidos hipofon&#233;ticos y soplo sist&#243;lico +++/4+ en &#225;rea a&#243;rtica. El h&#237;gado fue palpado a 2 cm del reborde costal derecho y hab&#237;a edema ++/4+ en miembros inferiores.</p>
      <p>La radiograf&#237;a de t&#243;rax revel&#243; aumento de la &#225;rea card&#237;aca de configuraci&#243;n redondeada.</p>
      <p>El electrocardiograma (5 jun 2004) revel&#243; flutter atrial, frecuencia card&#237;aca 79 lpm, bajo voltaje del complejo QRS en el plano frontal, eje QRS desviado para la derecha y anteriorizado y disminuici&#243;n de potenciales de ventr&#237;culo izquierdo, sugestivo de sobrecarga ventricular derecha y &#225;rea el&#233;ctricamente inactiva pared lateral (<xref ref-type="fig" rid="es_a21fig01m-body2">Figura 1</xref>).</p>
      <p content-type="asset">
        <fig id="es_a21fig01m-body2">
          <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf01-es.jpg"/></fig>
      </p>
      <p>El ecocardiograma (3 jun 2004) revel&#243; que las dimensiones del ventr&#237;culo izquierdo y del atrio izquierdo eran semejantes a las anteriormente medidas e hipertrofia del ventr&#237;culo derecho y gran derrame peric&#225;rdico, sin se&#241;ales de restricci&#243;n o taponamiento card&#237;aco. (<xref ref-type="table" rid="tab1-body2">Tab1</xref>).</p>
      <p>Fueron indicados drenaje y biopsia peric&#225;rdica. En la intervenci&#243;n (5 jun 2004) hubo drenaje de 450 ml de l&#237;quido citrino. El examen anatomopatol&#243;gico de los fragmentos de pericardio examinados revel&#243; discreta fibrosis y neovascularizaci&#243;n del pericardio, sin evidencia de c&#233;lulas neopl&#225;sicas o infiltrado inflamatorio.</p>
      <p>El ecocardiograma de control (15 jun 2004) revel&#243; derrame peric&#225;rdico discreto.</p>
      <p>Hubo mejora de la disnea y el paciente recibi&#243; alta hospitalaria (15 jun 2004).</p>
      <p>El mapeo del espesor mioc&#225;rdico por ecocardiograma (4 jun 2007) revel&#243; las siguientes medidas de los segmentos: anterior (basal 17 mm, medio 19 mm), anteroseptal (basal 20 mm, medio 22 mm), inferoseptal (basal 15 mm, medio 16 mm), inferior (basal y medio 11 mm) e inferolateral (basal 12, medio 13 mm), anterolateral (basal 11 mm, medio 15 mm), apical septal 14 mm, apical lateral 14 mm, calota apical 12 mm.</p>
      <p>El electrocardiograma de alta resoluci&#243;n (26 jul 2007) revel&#243; ensanchamiento del QRS - duraci&#243;n de QRS est&#225;ndar 140 ms; duraci&#243;n del QRS filtrado 130 ms; duraci&#243;n abajo de 40 mV 14 ms; y ausencia de potenciales tard&#237;os de baja amplitud en los 40 ms finales, 61,7 mV.</p>
      <p>La disnea a los esfuerzos moderados permaneci&#243; estable 4 a&#241;os m&#225;s, hasta que en mayo de 2008 progres&#243; hasta aparecer aun en reposo, en dec&#250;bito y surgir edema generalizado. Despu&#233;s de 20 d&#237;as, como no hubo mejora, procur&#243; nuevamente atenci&#243;n m&#233;dica (6 jun 2006).</p>
      <p>El examen f&#237;sico (6 jun 2008) revel&#243; paciente en regular estado general, con frecuencia de pulso de 90 lpm, presi&#243;n arterial 70/50 mm Hg. La presi&#243;n venosa yugular estaba elevada. La semiolog&#237;a pulmonar fue normal. La semiolog&#237;a card&#237;aca revel&#243; hipofonesis de ruidos y no hab&#237;a soplos. El abdomen era globoso y hab&#237;a ascitis, adem&#225;s de edema escrotal y de miembros inferiores ++++/4+.</p>
      <p>El ECG (6 jun 08) revel&#243; fibrilaci&#243;n atrial, frecuencia card&#237;aca 96 lpm, duraci&#243;n QRS 143 ms, bajo voltaje del complejo QRS, SAQRS + 130 para frente, bloqueo de rama derecha, con R puro en V1 y V2, y &#225;rea el&#233;ctricamente inactiva lateral (<xref ref-type="fig" rid="es_a21fig02m-body2">Figura 2</xref>).</p>
      <p content-type="asset">
        <fig id="es_a21fig02m-body2">
          <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf02-es.jpg"/></fig>
      </p>
      <p>La radiograf&#237;a de t&#243;rax (6 jun 2008) revel&#243; aumento global de &#225;rea card&#237;aca sin se&#241;ales de congesti&#243;n pulmonar.</p>
      <p>Los ex&#225;menes de laboratorio (6 jun 08) revelaron hemoglobina 11,5 g/dL, hematocrito 34%, leucocitos 6700/mm<sup>3</sup> (68% neutr&#243;filos, 1% eosin&#243;filos, 1% bas&#243;filos, 13% linfocitos y 17% monocitos), plaquetas 161000/mm<sup>3</sup>, urea 67 mg/ dL, creatinina 2,3 mg/ dL, potasio 3,6 mEq/L, sodio 136 mEq/L, tiempo de protrombina INR 2,7, relaci&#243;n de tiempos de tromboplastina activada 1,57, creatinofosfoquinasa fracci&#243;n MB masa 3,73 ng/mL y troponina I 0,21 ng/mL.</p>
      <p>El ecocardiograma (11 jun 08) revel&#243; hipocinesia del ventr&#237;culo izquierdo y derecho, y de insuficiencia tric&#250;spide acentuada y derrame peric&#225;rdico moderado. (<xref ref-type="table" rid="tab1-body2">Tab 1</xref>).</p>
      <p>La ultrasonograf&#237;a de abdomen total (12 jun 08) revel&#243; v&#237;as urinarias sin anormalidades, ectasia de la vena cava inferior y hep&#225;ticas, ascitis moderada, h&#237;gado con bordes romos y textura finamente heterog&#233;nea.</p>
      <p>Los ex&#225;menes de laboratorio (12 jun 08) revelaron creatinina 2,94 mg/ dL, urea 110 mg/ dL, potasio 5,9 mEq/L, sodio 134 mEq/L.</p>
      <p>La c&#225;mara gamma de ventilaci&#243;n y de perfusi&#243;n pulmonar (16 jun 08) fue considerada como de baja probabilidad de tromboembolismo pulmonar.</p>
      <p>La c&#225;mara gamma card&#237;aca con pirofosfato de tecnecio (20 jun 2008) revel&#243; captaci&#243;n discreta a moderada difusa en miocardio (<xref ref-type="fig" rid="fig3-body2">Figura 3</xref> y <xref ref-type="fig" rid="fig4-body2">4</xref>).</p>
      <fig id="fig3-body2">
        <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf03-es.jpg"/></fig>
      <fig id="fig4-body2">
        <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf04-es.jpg"/></fig>
      <p>La resonancia magn&#233;tica card&#237;aca (27 jun 06) revel&#243; dilataci&#243;n biatrial acentuada; c&#225;maras ventriculares de dimensiones normales; disfunci&#243;n ventricular izquierda discreta por hipocinesia difusa; funci&#243;n ventricular derecha normal. Hab&#237;a reflujo tric&#250;spide acentuado y moderado derrame peric&#225;rdico, derrame pleural bilateral y no hab&#237;a trombos. Los hallazgos fueron considerados compatibles con amiloidosis.</p>
      <p>La investigaci&#243;n de prote&#237;na de Bence Jones en la orina fue negativa.</p>
      <p>En la evoluci&#243;n el ecocardiograma (11 jul 08) revel&#243; derrame peric&#225;rdico acentuado (<xref ref-type="table" rid="tab1-body2">Tab. 1</xref>)</p>
      <p>A pesar del tratamiento con uso de diur&#233;ticos e inotr&#243;picos por v&#237;a intravenosa, hubo empeoramiento acentuado del cuadro con edema generalizado, derrame pleural y derrame peric&#225;rdico. Fue realizado otro drenaje peric&#225;rdico, adem&#225;s de paracentesis bilateral del t&#243;rax sin intercurrencias (18 jul 08).</p>
      <p>El paciente present&#243; tos con expectoraci&#243;n purulenta. Fueron identificados <italic>cocos gram positivos en el l&#237;quido pleural izquierdo. Fue iniciada la antibioticoterapia con oxacilina y ceftriaxona (21 jul 08) substituidos el d&#237;a siguiente por tazobactam y vancomicina.</italic></p>
      <p>La ultrasonograf&#237;a de abdomen total (22/07/08) revel&#243; hepatomegalia con forma y contornos normales y bordes romos; las v&#237;as biliares intra y extrahep&#225;ticas fueron normales y hab&#237;a esplenomegalia homog&#233;nea; ascitis moderada. Los ri&#241;ones estaban normales.</p>
      <p>Los ex&#225;menes de laboratorio (26 jul 2008) revelaron hemoglobina 10,5 g/dL, hematocrito 33%, leucocitos 36400/mm<sup>3</sup> (3% promielocitos, 2% mielocitos, 8% metamielocitos, 9% bastonetes, 63% segmentados, 2% eosin&#243;filos, 1% bas&#243;filos, 3% linfocitos y 9% monocitos), plaquetas 102000/mm<sup>3</sup>, urea 77 mg/ dL, creatinina 3 mg/ dL, bilirrubinas 7,8 mg/dl (directa 6,6 mg/dL), fosfatasa alcalina 107 UI/L, gama GT 215 UI/L, aspartato aminotransferasa 47 UI/mL, alanina aminotransferasa 45 UI/L, prote&#237;na C reactiva 163 mg/l, lactato arterial 52 mg/dL, tiempo de protrombina (INR) 2,1, relaci&#243;n TTPA 1,5, gasometr&#237;a arterial: pH 7,20, pCO2 39,5 mm Hg, pO2 75,7 mm Hg, saturaci&#243;n de O2 92,5%, bicarbonato 14,8 mEq/L y exceso de base -12,1mEq/L.</p>
      <p>A pesar de las medidas terap&#233;uticas el paciente evolucion&#243; en shock s&#233;ptico a partir de 23 jul 2008, se instal&#243; insuficiencia m&#250;ltiple de &#243;rganos y falleci&#243; en asistolia (27 jul 2008).</p>
      <p>
        <bold>Aspectos cl&#237;nicos</bold>
      </p>
      <p>El paciente, en su cuadro cl&#237;nico inicial, a los 33 a&#241;os de edad, se present&#243; con queja de disnea desencadenada por esfuerzos. En ese momento, hab&#237;a importancia en tratar de definir el origen m&#225;s probable de la queja. Cuando es resultante de cardiopat&#237;a, la disnea se asocia a aumento de la presi&#243;n capilar pulmonar, con consecuente congesti&#243;n intersticial secundaria. Otras potenciales causas ser&#237;an pulmonares, por alteraciones tiroideas, anemia, etc.<sup>1,2</sup>. La presencia de aumento del &#225;rea card&#237;aca relatada en la primera radiograf&#237;a de t&#243;rax aumenta, ya en ese momento, la probabilidad de que el origen fuese card&#237;aco.</p>
      <p>Se trata, por lo tanto, de paciente con insuficiencia card&#237;aca (IC), que podr&#237;a ser consecuencia de disfunci&#243;n sist&#243;lica (fracci&#243;n de eyecci&#243;n - FE - menor que 50%) o diast&#243;lica del ventr&#237;culo izquierdo (VI) (dificultad anormal para el llenado del VI en la di&#225;stole)<sup>3</sup>.</p>
      <p>Disfunci&#243;n diast&#243;lica es la causa de IC en 40 a 50% de los pacientes. Para el diagn&#243;stico de insuficiencia card&#237;aca con fracci&#243;n de eyecci&#243;n preservada (ICFEP) y disfunci&#243;n diast&#243;lica es necesaria la presencia simult&#225;nea de tres factores: se&#241;ales o s&#237;ntomas de IC congestiva; FE de VI normal o discretamente reducida; y evidencias objetivas de disfunci&#243;n diast&#243;lica de VI: relajaci&#243;n y llenado anormal del VI, distensibilidad diast&#243;lica anormal o rigidez diast&#243;lica. Las evidencias de disfunci&#243;n diast&#243;lica pueden ser obtenidas a partir de datos hemodin&#225;micos, niveles de p&#233;ptidos natriur&#233;ticos, datos ecocardiogr&#225;ficos y del Doppler tisular<sup>4</sup>.</p>
      <p>La evoluci&#243;n con dolor precordial y palpitaciones, despu&#233;s de 2 a&#241;os, sin alteraciones significativas en el examen f&#237;sico, con hipertrofia ventricular y fracci&#243;n de eyecci&#243;n normal en el ecocardiograma, adem&#225;s de derrame peric&#225;rdico y ausencia de coronariopat&#237;a, nos remite a las posibilidades de enfermedad card&#237;aca hipertensiva, miocarditis acompa&#241;ada de afectaci&#243;n peric&#225;rdica, cardiomiopat&#237;a hipertr&#243;fica (CMH) y s&#237;ndromes restrictivos, como las enfermedades de dep&#243;sito.</p>
      <p>La enfermedad card&#237;aca hipertensiva puede ser definida como resultado de la sobrecarga impuesta al VI por el aumento de la presi&#243;n arterial y de la resistencia vascular perif&#233;rica total. En ese caso, se trata de un paciente joven con hipertrofia ventricular izquierda (HVI) evolucionando con ICFEP. Como consecuencia de la HVI se puede observar incidencia aumentada de algunas arritmias, como extras&#237;stoles ventriculares, arritmias ventriculares complejas<sup>5</sup> y fibrilaci&#243;n atrial (FA), lo que justificar&#237;a las taquiarritmias presentadas por el paciente.</p>
      <p>Para el diagn&#243;stico de HVI, el electrocardiograma (ECG) es un m&#233;todo poco sensible, sin embargo bastante espec&#237;fico, entre tanto los hallazgos del paciente en discusi&#243;n no llenan esos criterios. Ya el ecocardiograma es un m&#233;todo de bajo costo y es considerado el m&#233;todo no invasivo de elecci&#243;n para el diagn&#243;stico de aumento de masa card&#237;aca. Se podr&#237;a pensar en investigaci&#243;n de hipertensi&#243;n secundaria por tratarse de un paciente joven con HVI. Sin embargo, en ese caso, una vez que el paciente aparentemente obtuvo control pres&#243;rico utilizando apenas 5 mg de enalapril, por lo tanto con f&#225;cil control pres&#243;rico, por la evoluci&#243;n presentada y por el hecho de que la hipertrofia es claramente asim&#233;trica, la hip&#243;tesis de enfermedad card&#237;aca hipertensiva podr&#237;a ser descartada<sup>6,7</sup>.</p>
      <p>Las miocarditis, que son m&#225;s frecuentemente causadas por agentes virales<sup>8</sup>, poseen un amplio espectro de presentaci&#243;n cl&#237;nica, que var&#237;a desde cuadros subcl&#237;nicos u oligosintom&#225;ticos hasta la muerte s&#250;bita card&#237;aca. La infecci&#243;n por algunos agentes espec&#237;ficos puede estar asociada a presentaciones menos frecuentes, como el fenotipo de cardiomiopat&#237;a hipertr&#243;fica sin disfunci&#243;n ventricular - inicialmente presentado por el caso en cuesti&#243;n - que puede ser causado por el virus de la hepatitis C, siendo &#233;ste de mayor prevalencia en poblaciones de pa&#237;ses asi&#225;ticos<sup>9</sup>. Tambi&#233;n en la miocarditis fulminante, caracterizada por presentaci&#243;n aguda muy grave, inclusive con shock cardiog&#233;nico, se observa, en la evaluaci&#243;n ecocardiogr&#225;fica, un aumento del espesor septal con menor aumento de los di&#225;metros ventriculares.</p>
      <p>La presencia de arritmias asociadas a las alteraciones mioc&#225;rdicas es tambi&#233;n frecuente en las miocarditis, necesitando muchas veces tratamiento espec&#237;fico, y/o siendo indicador de posible evoluci&#243;n desfavorable de la enfermedad, como ocurre en la miocarditis de c&#233;lulas gigantes. En ese tipo espec&#237;fico de inflamaci&#243;n mioc&#225;rdica, entre tanto, seria esperada una historia de menor duraci&#243;n - diferentemente de lo presentado por el caso -, una vez que los pacientes presentan malmalu pron&#243;stico, con sobrevida media de menos de 6 meses, y necesidad muy frecuente de transplante card&#237;aco cuando sobreviven al cuadro agudo<sup>8</sup>. La miocarditis cr&#243;nica activa, por su vez, caracter&#237;sticamente tendr&#237;a una evoluci&#243;n m&#225;s prolongada e insidiosa, en general con manifestaci&#243;n fenot&#237;pica de cardiomiopat&#237;a dilatada, llegando a &#237;ndices de mortalidad de 56% en 4 a&#241;os. Puede aun ocurrir afectaci&#243;n peric&#225;rdica asociada a las miocarditis<sup>8</sup>.</p>
      <p>Otra hip&#243;tesis para el caso son las cardiomiopat&#237;as restrictivas e infiltrativas, que se caracterizan por limitaci&#243;n del llenado ventricular y rigidez ventricular, con ventr&#237;culos normales o discretamente dilatados y dilataci&#243;n atrial importante<sup>9</sup>. El espesor ventricular es normal o aumentado, dependiendo de la etiolog&#237;a. Los s&#237;ntomas pueden ser consecuencia de la insuficiencia del ventr&#237;culo derecho (VD), que se manifiesta con aumento de la presi&#243;n venosa yugular, edema perif&#233;rico y ascitis y/o insuficiencia del VI, ocasionando disnea y edema pulmonar<sup>10,11</sup>. La cardiomiopat&#237;a restrictiva es la m&#225;s rara de las cardiomiopat&#237;as, siendo la amiloidosis su forma m&#225;s com&#250;n<sup>12</sup>.</p>
      <p>Como una de las causas de cardiomiopat&#237;a restrictiva, la sarcoidosis es una enfermedad granulomatosa sist&#233;mica de etiolog&#237;a desconocida, caracterizada por el envolvimiento de varios tejidos por granulomas no gaseosos<sup>13</sup>. El envolvimiento card&#237;aco primario es infrecuente y las manifestaciones cl&#237;nicas aparecen en menos de 5% de los pacientes y se caracterizan por disturbios de conducci&#243;n, arritmias ventriculares, s&#237;ncope y muerte s&#250;bita. El envolvimiento mioc&#225;rdico directo por los granulomas y tejido cicatricial puede manifestarse en forma de cardiomiopat&#237;a dilatada o restrictiva, con curso progresivo<sup>14,15</sup>. El ECG es inespec&#237;fico, pudiendo presentar anormalidades de la onda T, bloqueos u ondas Q patol&#243;gicas. Otros hallazgos incluyen pericarditis y cor pulmonale. El ecocardiograma puede revelar adelgazamiento de las paredes ventriculares y aumento de la ecogenicidad<sup>14,16</sup>. La resonancia magn&#233;tica card&#237;aca (RMC) es un m&#233;todo altamente sensible y espec&#237;fico para su diagn&#243;stico. El caso presentado muestra apenas afectaci&#243;n card&#237;aca sin las dem&#225;s manifestaciones de esa enfermedad, y la RMC no evidenci&#243; alteraciones sugestivas, lo que vuelve poco probable que sea ese el diagn&#243;stico del paciente<sup>17</sup>.</p>
      <p>La enfermedad de Fabry es un disturbio hereditario con herencia recesiva ligada al cromosoma X, resultante de la deficiencia de la enzima lisos&#243;mica alfa galactosidasa A. En su forma cl&#225;sica, se caracteriza por envolvimiento acentuado de la piel, de los ri&#241;ones y del miocardio, incluyendo la manifestaci&#243;n de angina pectoris e infarto de miocardio, aunque la mayor&#237;a de las veces las arterias coronarias tengan aspecto angiogr&#225;fico normal. Hay aumento del espesor del VI, con funci&#243;n sist&#243;lica preservada y discretas disfunci&#243;n diast&#243;lica e insuficiencia mitral. La RMC es adecuada para diferenciar la enfermedad de Fabry de otras cardiomiopat&#237;as<sup>10,11</sup>. El paciente en discusi&#243;n no presenta manifestaciones extracard&#237;acas compatibles con la enfermedad y la RMC es sugestiva de otra enfermedad.</p>
      <p>La hemocromatosis resulta del dep&#243;sito de hierro en tejidos parenquimatosos, como coraz&#243;n, h&#237;gado, g&#243;nadas y p&#225;ncreas. Su presentaci&#243;n cl&#225;sica es a trav&#233;s de la aparici&#243;n de insuficiencia card&#237;aca, cirrosis hep&#225;tica, disfunci&#243;n er&#233;ctil, diabetes mellitus y artritis. El envolvimiento card&#237;aco lleva al est&#225;ndar combinado de cardiomiopat&#237;a dilatada y cardiomiopat&#237;a restrictiva con disfunciones sist&#243;lica y diast&#243;lica. El ECG incluye alteraciones del segmento ST y de la onda T y arritmias supraventriculares. El ecocardiograma revela engrosamiento de pared, dilataci&#243;n y disfunci&#243;n ventriculares. Los marcadores de cin&#233;tica del hierro se muestran alterados<sup>10,11</sup>. La RMC con adquisici&#243;n con la t&#233;cnica T2 estrella puede cerrar el diagn&#243;stico<sup>18</sup>. En el paciente en cuesti&#243;n, no hay manifestaciones extracard&#237;acas sugestivas y los ex&#225;menes complementarios no son compatibles con hemocromatosis.</p>
      <p>Las enfermedades endomioc&#225;rdicas se manifiestan con fibrosis endoc&#225;rdica que oblitera el &#225;pice de los ventr&#237;culos y las regiones subvalvares<sup>10,11</sup>. Como se puede observar, ese no es el est&#225;ndar del paciente en discusi&#243;n.</p>
      <p>La amiloidosis es una enfermedad de dep&#243;sito que puede ser clasificada de acuerdo con la naturaleza bioqu&#237;mica de la prote&#237;na amiloide en amiloidosis primaria, secundaria, senil, familiar y amiloidosis de los pacientes con insuficiencia renal dial&#237;tica. Debe ser considerada como diagn&#243;stico diferencial en cualquier paciente con m&#225;s de 40 a&#241;os con insuficiencia card&#237;aca inexplicable, s&#237;ndrome nefr&#243;tica, neuropat&#237;a perif&#233;rica o hepatopat&#237;a. La amiloidosis secundaria y la amiloidosis de los pacientes renales cr&#243;nicos raramente presentan envolvimiento card&#237;aco. En el ECG son encontrados bloqueos atrioventriculares y complejos QRS de bajo voltaje, y el ECG de alta resoluci&#243;n tiene valor en la predicci&#243;n del riesgo de muerte s&#250;bita, diferentemente de lo que ocurre en los casos de CMH. De forma semejante a esa otra enfermedad, entre tanto, la infiltraci&#243;n amiloide tambi&#233;n predispone a FA y arritmias ventriculares<sup>10,11,19,20</sup>.</p>
      <p>El ecocardiograma muestra aumento del espesor mioc&#225;rdico, que tiene aspecto granuloso, dilataci&#243;n de atrios, derrame peric&#225;rdico, pleural o ambos y disfunci&#243;n diast&#243;lica. El derrame peric&#225;rdico no evoluciona habitualmente a taponamiento card&#237;aco, y la presencia de disfunci&#243;n del VD es un predictor independiente de mal pron&#243;stico<sup>10,11</sup>. La c&#225;mara gamma con pirofosfato de tecnecio muestra captaci&#243;n proporcional a la intensidad del dep&#243;sito amiloide<sup>11</sup>. Una vez que ese radiois&#243;topo es capaz de ligarse al calcio, el examen puede estar alterado tambi&#233;n en otras situaciones, como calcificaciones y otras enfermedades de dep&#243;sito. La RMC tiene alta sensibilidad y especificidad que puede variar de 75% a 94%, cuando es encontrado est&#225;ndar caracterizado por realce global y heterog&#233;neo subendoc&#225;rdico tard&#237;o con gadolinio<sup>17,21,22</sup>, en cuanto la biopsia caracteriza la substancia amiloide y confirma la sospecha de amiloidosis.</p>
      <p>En el caso en discusi&#243;n, inicialmente el diagn&#243;stico de amiloidosis parece poco probable por la edad del paciente y por el ECG presentado. Entre tanto, en la evoluci&#243;n del caso el cambio del est&#225;ndar electrocardiogr&#225;fico se aproxima m&#225;s de aquel com&#250;n a los casos de amiloidosis (bajo voltaje), no siendo posible, sin embargo, establecer si esto no habr&#237;a ocurrido apenas por el derrame peric&#225;rdico. Adem&#225;s, la investigaci&#243;n de la prote&#237;na de Bence Jones fue negativa. Por otro lado, el paciente presenta s&#237;ndrome restrictivo grave y fue realizada c&#225;mara gamma con pirofosfato y RMC que son compatibles con ese diagn&#243;stico. De esa forma, ser&#237;a posible pensar en amiloidosis card&#237;aca, en su forma primaria, como el diagn&#243;stico del caso presentado.</p>
      <p>Un diagn&#243;stico diferencial de la cardiomiopat&#237;a restrictiva es la pericarditis constrictiva, caracterizada por fibrosis peric&#225;rdica que impide el llenado de las c&#225;maras card&#237;acas. Ocurre congesti&#243;n venosa sist&#233;mica y reducci&#243;n del &#237;ndice card&#237;aco. El ECG revela, normalmente, alteraciones inespec&#237;ficas de la onda T y reducci&#243;n del voltaje, adem&#225;s de se&#241;ales de sobrecarga atrial izquierda o FA. La radiograf&#237;a de t&#243;rax muestra aumento atrial derecho y el ecocardiograma puede revelar calcificaciones peric&#225;rdicas y derrame peric&#225;rdico. Entre tanto, en el presente caso, fueron observados aumento del espesor de la pared ventricular, presi&#243;n sist&#243;lica de arteria pulmonar superior a 50mmHg y RMC sin engrosamiento peric&#225;rdico, siendo todas esas alteraciones sugestivas de s&#237;ndrome restrictiva, y no constrictiva<sup>10,11</sup>.</p>
      <p>Por fin, la CMH constituye la enfermedad card&#237;aca gen&#233;tica de mayor prevalencia<sup>23</sup> y la causa m&#225;s com&#250;n de muerte s&#250;bita card&#237;aca en personas j&#243;venes<sup>24</sup>. Es caracter&#237;stico de la enfermedad un est&#225;ndar asim&#233;trico de hipertrofia, habiendo m&#225;s frecuentemente (en 70% a 75% de los casos) evidencia ecocardiogr&#225;fica de hipertrofia difusa del septo ventricular y de la pared anterolateral, as&#237; como descripci&#243;n de hipertrofia de ventr&#237;culo derecho en algunos pacientes<sup>25</sup>. Las manifestaciones cl&#237;nicas pueden surgir a cualquier edad, siendo m&#225;s frecuente el diagn&#243;stico durante la adolescencia y el inicio de la vida adulta.</p>
      <p>La desorganizaci&#243;n de la arquitectura mioc&#225;rdica inducida por la enfermedad, asociada al aumento de la masa ventricular y a alteraciones presentes en la microvascularizaci&#243;n coronaria llevan a isquemia mioc&#225;rdica silenciosa, con formaci&#243;n de &#225;reas de fibrosis, que pueden corresponder a regiones el&#233;ctricamente inestables, de donde pueden originarse arritmias ventriculares. Adem&#225;s de eso, esas &#225;reas de fibrosis, asociadas a hipertrofia regional (en general, septal), pueden llevar a alteraciones en el ECG, con sobrecarga atrial, por ejemplo, ondas R en V1, disminuci&#243;n de ondas R y surgimiento de ondas Q en derivaciones de pared lateral (DI, aVL, V5 y V6), alteraciones de repolarizaci&#243;n ventricular y, en caso de fibrosis en pared lateral, desv&#237;o del eje a la derecha, como puede ser observado en el paciente en cuesti&#243;n. En la evoluci&#243;n de la enfermedad, puede aun ocurrir, de modo compatible con este caso, ensanchamiento del QRS<sup>26</sup>.</p>
      <p>Los pacientes pueden presentar obstrucci&#243;n a la v&#237;a de salida del VI, que est&#225; relacionada al desarrollo del cuadro cl&#237;nico de insuficiencia card&#237;aca, a mayor tasa de &#243;bito cardiovascular y a mayor riesgo de muerte s&#250;bita<sup>3</sup>, y que es reducida con el uso de betabloqueantes, y aumentada, entre otras situaciones, en la presencia de extras&#237;stoles ventriculares (EV) y en la maniobra de Valsalva.</p>
      <p>El paciente en cuesti&#243;n present&#243; empeoramiento cl&#237;nico despu&#233;s de la suspensi&#243;n de amiodarona e inicio del uso de atenolol. En caso de ser CMH el diagn&#243;stico, y por lo tanto el uso de betabloqueante haber sido correctamente indicado, la suspensi&#243;n de la amiodarona puede haberse asociado a un aumento en la frecuencia de EV, con consecuente aumento del gradiente suba&#243;rtico, pudiendo haber llevado al surgimiento de componente obstructivo en la enfermedad generando, as&#237;, el empeoramiento del s&#237;ntoma de disnea. Otra posible causa del empeoramiento con la suspensi&#243;n de la amiodarona habr&#237;a sido la mayor incidencia de arritmias parox&#237;sticas supraventriculares, como la FA, reconocidamente asociadas a empeoramiento cl&#237;nico de esos pacientes, con empeoramiento del pron&#243;stico<sup>23,26</sup>. Se sabe que la incidencia de arritmias supraventriculares, incluyendo FA, por registros en Holter, puede llegar hasta 30% en adultos<sup>26</sup>. La presencia de FA en esa poblaci&#243;n, aun en el primer o segundo episodio parox&#237;stico, es capaz de generar formaci&#243;n de trombos y fen&#243;menos cardioemb&#243;licos, haciendo que haya indicaci&#243;n de anticoagulaci&#243;n en esos pacientes, con bajo umbral para su comienzo<sup>24,27</sup>.</p>
      <p>Diez a 15% de los pacientes evolucionan con insuficiencia card&#237;aca limitante (clase funcional New York Heart Association III o IV), y apenas 3% manifiestan enfermedad avanzada con FE de VI menor que 50%<sup>28</sup>. Un estudio publicado en 2007 mostr&#243;, entre 1.226 pacientes con diagn&#243;stico de CMH, poblaciones de fenotipo del tipo restrictivo de 1,5%<sup>29</sup>. Los pacientes con el fenotipo estudiado presentaron m&#225;s disfunci&#243;n diast&#243;lica y mayor di&#225;metro atrial izquierdo, adem&#225;s de menor tolerancia al ejercicio y peor pron&#243;stico, con sobrevida de 56% en 5 a&#241;os - versus 90% en aquellos sin el fenotipo del tipo restrictivo (p=0,008) - habiendo sido observadas, en 42% de los casos, se&#241;ales de insuficiencia card&#237;aca derecha, como ascitis, disconfort abdominal y edema. Hubo, aun, mayor tendencia al desarrollo de FA o flutter atrial y mayores tasas de accidente cerebro vascular . Se puede observar que, durante su evoluci&#243;n, el paciente relatado present&#243; diversas caracter&#237;sticas compatibles con ese fenotipo de la enfermedad.</p>
      <p>Delante de la posibilidad de ocurrencia de muerte s&#250;bita, estudios previos definieron marcadores de riesgo, utilizados en la estratificaci&#243;n de esos pacientes. Aquellos diagnosticados antes de los 14 a&#241;os de edad presentan mayor riesgo. Otros factores incluyen: historia personal de s&#237;ncope o muerte s&#250;bita revertida; historia familiar de muerte s&#250;bita; hipertrofia grave (mayor que 30mm)<sup>30</sup>; presencia de taquicardia ventricular no sustentada (TVNS) en el monitoreo por Holter; comportamiento pres&#243;rico anormal al esfuerzo - ca&#237;da de la presi&#243;n arterial o aumento menor que 25mm Hg de la presi&#243;n sist&#243;lica<sup>26</sup>. El ECG de alta resoluci&#243;n, el an&#225;lisis de la dispersi&#243;n del intervalo QT y de la variabilidad de la frecuencia card&#237;aca presentan baja precisi&#243;n predictiva<sup>31</sup>. En el caso en cuesti&#243;n, el paciente present&#243;, entre los factores de riesgo listados, TVNS en el monitoreo por Holter, y no tuvo una curva pres&#243;rica que pudiese ser evaluada en el test ergom&#233;trico, debido al bajo trabajo realizado.</p>
      <p>El cuadro cl&#237;nico tuvo un car&#225;cter progresivo, desde su diagn&#243;stico, caracterizado por tres episodios m&#225;s importantes de descompensaci&#243;n, con alteraciones cl&#237;nicas, electrocardiogr&#225;ficas y ecocardiogr&#225;ficas cada vez m&#225;s significativas. En su &#250;ltima internaci&#243;n, el paciente evolucion&#243; con disfunci&#243;n sist&#243;lica biventricular, derrame peric&#225;rdico acentuado, edema, ascitis y shock cardiog&#233;nico, acompa&#241;ados por insuficiencia renal, coagulopat&#237;a e infecci&#243;n pulmonar complicada con shock s&#233;ptico, culminando en &#243;bito.</p>
      <p>Considerando la edad de la presentaci&#243;n inicial, las alteraciones cl&#237;nicas encontradas a lo largo de los a&#241;os de evoluci&#243;n, las alteraciones en los ex&#225;menes subsidiarios realizados y las caracter&#237;sticas de cada una de las enfermedades presentadas a lo largo de esta discusi&#243;n, consideramos la CMH como la principal hip&#243;tesis diagn&#243;stica en ese caso.</p>
      <p>Dr. Rafael Moura de Almeida y</p>
      <p> Dr. Lucas Jos&#233; Tachotti Pires</p>
      <p>
        <bold>Hip&#243;tesis diagn&#243;stica</bold>
      </p>
      <p>S&#237;ndrome restrictivo secundario a cardiomiopat&#237;a hipertr&#243;fica.</p>
      <p>Dr. Rafael Moura de Almeida y</p>
      <p> Dr. Lucas Jos&#233; Tachotti Pires</p>
      <p>
        <bold>C&#225;mara gamm</bold>
      </p>
      <p>C&#225;mara gamma con 99mTc-pirofosfato de 20 de junio de 2008 (<xref ref-type="fig" rid="fig3-body2">Figuras 3</xref> ey <xref ref-type="fig" rid="fig4-body2">4</xref>).</p>
      <p>Las im&#225;genes de c&#225;mara gamma del t&#243;rax, realizadas 3 horas despu&#233;s de la administraci&#243;n endovenosa del 99mTc-pirofosfato, obtenidas en las proyecciones anterior y oblicua anterior izquierda de 60&#186; demuestran captaci&#243;n difusa en la proyecci&#243;n card&#237;aca de grado discreto/moderado.</p>
      <p>El 99mTc-pirofosfato se liga al calcio intracelular, que se acumula en las c&#233;lulas debido a alteraciones del sarcolema. Es importante resaltar que el miocardio normal no presenta captaci&#243;n de 99mTc-pirofosfato. El examen era muy utilizado en el pasado para evaluaci&#243;n de infarto agudo de miocardio, donde el est&#225;ndar cl&#225;sico es de captaci&#243;n focal en la pared atacada. La captaci&#243;n difusa es un hallazgo infrecuente y poco espec&#237;fico, generalmente relacionado a enfermedades que atacan el coraz&#243;n difusamente como amiloidosis, sarcoidosis, perimiocarditis, endocarditis o infarto subendoc&#225;rdico. En la amiloidosis el grado de captaci&#243;n est&#225; relacionado con el grado de engrosamiento del miocardio, por lo tanto con implicaciones pron&#243;sticas<sup>32,33</sup>. En el caso en cuesti&#243;n, la captaci&#243;n difusa en cardiomiopat&#237;a hipertr&#243;fica no es esperada, pudiendo estar relacionada a los hallazgos de la necropsia de infarto subendoc&#225;rdico y/o pericarditis.</p>
      <p>Dr. Jos&#233; Soares Junior</p>
      <p> Dr. Wilson Ichiki y Dr. Wilson Andr&#233; Ichiki</p>
      <p>
        <bold>Necropsia</bold>
      </p>
      <p>A la apertura del saco peric&#225;rdico hubo salida de cerca de 250ml de sangre y co&#225;gulos, observ&#225;ndose pericarditis fibrinosa, difusa. El coraz&#243;n pes&#243; 510g (normal: 300-350g) y exhib&#237;a aumento del volumen de las cuatro c&#225;maras card&#237;acas. Hab&#237;a dilataci&#243;n moderada del ventr&#237;culo derecho y de los atrios. Los ventr&#237;culos presentaban hipertrofia moderada y sim&#233;trica, con relaci&#243;n entre los espesores del septo ventricular y de la pared libre del ventr&#237;culo izquierdo = 1,2, sin obstrucci&#243;n cavitaria, not&#225;ndose extensas &#225;reas de fibrosis en el miocardio del ventr&#237;culo izquierdo (<xref ref-type="fig" rid="fig5-body2">Figuras 5</xref> y <xref ref-type="fig" rid="fig6-body2">6</xref>). El endocardio de ambos ventr&#237;culos era delgado, liso y brillante. En la aur&#237;cula derecha hab&#237;a un peque&#241;o trombo mixto, en organizaci&#243;n. No fueron encontradas anormalidades en las v&#225;lvulas atrioventriculares o ventr&#237;culo-arteriales. El estudio de las arterias coronarias evidenci&#243; trayecto intramioc&#225;rdico ("puente mioc&#225;rdico") del 2&#186; al 4&#186; cm del ramo interventricular izquierdo (<xref ref-type="fig" rid="fig7-body2">Figura 7</xref>) y, a la histolog&#237;a, hab&#237;a aterosclerosis coronaria leve, con obstrucci&#243;n m&#225;xima de 30% de la luz de las arterias coronarias principales.</p>
      <fig id="fig5-body2">
        <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf05-es.jpg"/></fig>
      <fig id="fig6-body2">
        <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf06-es.jpg"/></fig>
      <fig id="fig7-body2">
        <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf07-es.jpg"/></fig>
      <p>Cortes histol&#243;gicos de los ventr&#237;culos mostraron hipertrofia mioc&#225;rdica difusa, desarreglo espacial de cardiomiocitos y de haces de fibras card&#237;acas en m&#225;s de 20% de las &#225;reas muestreadas, fibrosis intersticial difusa desde la regi&#243;n subendoc&#225;rdica hasta la subepic&#225;rdica, y engrosamiento de la pared de las arterias coronarias intramurales debido a proliferaci&#243;n mediointimal de c&#233;lulas musculares lisas (<xref ref-type="fig" rid="es_a21fig08m-body2">figura 8</xref>). Aunque presentes en ambos ventr&#237;culos, esas alteraciones eran m&#225;s acentuadas en el septo ventricular y en la pared libre del ventr&#237;culo izquierdo. Las pesquisas histoqu&#237;micas de sustancia amil&#243;oide y de gluc&#243;geno en el miocardio resultaron negativas. Delante de los hallazgos anatomopatol&#243;gicos de la necropsia, se hace el diagn&#243;stico de cardiomiopat&#237;a hipertr&#243;fica, forma restrictiva, sin obstrucci&#243;n dade la viav&#237;a de sali&#237;da. Se observ&#243;, aun, congesti&#243;n pasiva cr&#243;nica en pulmones, h&#237;gado y bazo y edema generalizado de tejido subcut&#225;neo, consecuentes a insuficiencia card&#237;aca congestiva.</p>
      <p content-type="asset">
        <fig id="es_a21fig08m-body2">
          <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf08-es.jpg"/></fig>
      </p>
      <p>En los dem&#225;s &#243;rganos fueron encontradas alteraciones secundarias al shock, representadas por da&#241;o alveolar difuso y hemorragia intraalveolar en los pulmones, necrosis tubular aguda en los ri&#241;ones, necrosis hep&#225;tica centrilobular e infartos subendoc&#225;rdicos recientes, peque&#241;os y multifocales. En los pulmones hab&#237;a &#225;reas localizadas de bronconeumon&#237;a en fase inicial. Sin embargo, no fueron observadas alteraciones morfol&#243;gicas sugestivas de infecci&#243;n en otros &#243;rganos. La presencia de sangre y co&#225;gulos en el saco peric&#225;rdico pareci&#243; ser m&#225;s un evento final, resultado de las maniobras de resucitaci&#243;n.</p>
      <p>La causa del &#243;bito fue insuficiencia de m&#250;ltiples &#243;rganos consecuencia de shock, predominantemente cardiog&#233;nico y agravado por la infecci&#243;n pulmonar.</p>
      <p>
        <bold>L&#233;a Maria Macruz Ferreira Demarchi</bold>
      </p>
      <p>
        <bold>Diagn&#243;sticos anatomopatol&#243;gicos</bold>
      </p>
      <p>1) Cardiomiopat&#237;a hipertr&#243;fica sim&#233;trica, no obstructiva; 2) Insuficiencia card&#237;aca congestiva; 3) Shock mixto (cardiog&#233;nico/infeccioso); 4) Insuficiencia de m&#250;ltiples &#243;rganos.</p>
      <p>
        <bold>L&#233;a Maria Macruz Ferreira Demarchi</bold>
      </p>
      <p>
        <bold>Comentario</bold>
      </p>
      <p>La cardiomiopat&#237;a hipertr&#243;fica (CMH) es definida como cardiomiopat&#237;a primaria gen&#233;tica, caracterizada morfol&#243;gicamente por hipertrofia no dilatada del ventr&#237;culo izquierdo, en la ausencia de otra enfermedad sist&#233;mica o card&#237;aca capaz de causar tal alteraci&#243;n ventricular, como por ejemplo, la hipertensi&#243;n arterial sist&#233;mica y la estenosis de v&#225;lvula a&#243;rtica<sup>34</sup>.</p>
      <p>Tiene espectro cl&#237;nico abarcador, exhibiendo gran variabilidad morfol&#243;gica, de s&#237;ntomas y riesgo de complicaciones como muerte s&#250;bita y insuficiencia card&#237;aca<sup>35</sup>.</p>
      <p>Las principales caracter&#237;sticas anat&#243;micas de la CMH fueron obtenidas a partir de datos de observaci&#243;n de necropsias y son as&#237; definidas<sup>34</sup>: hipertrofia mioc&#225;rdica, desarreglo espacial de cardiomiocitos, arterias coronarias intramurales con alteraciones obstructivas y fibrosis mioc&#225;rdica.</p>
      <p>La hipertrofia mioc&#225;rdica puede ser asim&#233;trica o sim&#233;trica. La forma de presentaci&#243;n m&#225;s com&#250;n es la asim&#233;trica, caracterizada por hipertrofia m&#225;s acentuada del septo ventricular, siendo que la relaci&#243;n entre los espesores del septo ventricular/pared lateral del ventr&#237;culo izquierdo debe ser igual o mayor que 1,3<sup>36</sup>. Cuando est&#225; localizada en la porci&#243;n basal del septo ventricular, la hipertrofia causa obstrucci&#243;n de la v&#237;a de salida del ventr&#237;culo izquierdo y, consecuentemente, hay engrosamiento de la c&#250;spide anterior mitral y fibrosis endoc&#225;rdica septal suba&#243;rtica. Debido a la fricci&#243;n constante entre la hoja valvar y el endocardio septal, la fibrosis endoc&#225;rdica puede adquirir el formato de imagen en espejo de la c&#250;spide anterior mitral. La forma sim&#233;trica se caracteriza por hipertrofia conc&#233;ntrica del ventr&#237;culo izquierdo, sin obstrucci&#243;n de la v&#237;a de salida ventricular.</p>
      <p>En la CMH, el desarreglo espacial de cardiomiocitos debe estar presente en m&#225;s de 20% de las &#225;reas histol&#243;gicamente muestreadas<sup>37</sup> y se caracteriza por conexiones intercelulares m&#250;ltiples y ca&#243;ticas, bajo la forma de &#225;ngulos rectos y oblicuos<sup>34</sup>. Puede ser encontrado en cualquier pared de ambos ventr&#237;culos y, m&#225;s frecuentemente, ocupa grandes porciones del ventr&#237;culo izquierdo. &#193;reas extensas de desarreglo son descritas en pacientes j&#243;venes que murieron a consecuencia de la enfermedad<sup>34</sup>.</p>
      <p>Las arterias coronarias intramurales presentan alteraciones obstructivas caracterizadas por engrosamiento de pared y estrechamiento luminal, debido al aumento de dep&#243;sito de col&#225;geno en las t&#250;nicas &#237;ntima y media. Tales alteraciones, asociadas a la desproporci&#243;n entre la hipertrofia de la masa ventricular y la circulaci&#243;n coronaria, resultan en isquemia mioc&#225;rdica y consecuente fibrosis, que puede ser focal o transmural<sup>34</sup>.</p>
      <p>Otro hallazgo frecuente en la CMH es el trayecto intramural o "puente mioc&#225;rdico" de la rama interventricular anterior de la arteria coronaria izquierda, que tambi&#233;n fue observado en ese enfermo, pero su significado fisiopatol&#243;gico aun no est&#225; totalmente aclarado<sup>38</sup>.</p>
      <p>La contribuci&#243;n de la biopsia endomioc&#225;rdica (BEM) para el diagn&#243;stico de la cardiomiopat&#237;a hipertr&#243;fica es bastante limitada y, en el caso en discusi&#243;n, no mostr&#243; desarreglo mioc&#225;rdico, apenas hipertrofia de cardiomiocitos. En la CMH, las &#225;reas de desarreglo se localizan frecuentemente en regiones m&#225;s profundas de la pared ventricular, distantes de la regi&#243;n subendoc&#225;rdica, y, por lo tanto, fuera del alcance del bi&#243;tomo. Sin embargo, la BEM se muestra &#250;til para el diagn&#243;stico diferencial entre otras causas de hipertrofia ventricular, como amiloidosis, enfermedad de Pompe y, hasta aun, neoplasias<sup>37,39</sup>.</p>
      <p>Los hallazgos anatomopatol&#243;gicos obtenidos por la necropsia, asociados a los datos cl&#237;nicos y de ex&#225;menes complementarios, fueron fundamentales para el diagn&#243;stico de CMH en ese enfermo.</p>
      <p>
        <bold>Dra. L&#233;a Maria Macruz Ferreira Demarchi</bold>
      </p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Anatomopathological Session</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Case 5/2010: a 41 year-old man with myocardial hypertrophy who evolved with congestive heart failure</article-title>
      </title-group>
      <kwd-group xml:lang="en">
        <kwd>Heart failure</kwd>
        <kwd>hypertrophy</kwd>
        <kwd>left ventricular</kwd>
        <kwd>hypertension</kwd>
        <kwd>atrial fibrillation</kwd>
        <kwd>amyloidosis</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ANATOMOPATHOLOGICAL SESSION</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>Case 5/2010 - a 41 year-old man with myocardial hypertrophy who evolved with congestive heart failure</bold>
          </label>
          <p>
            <bold>Rafael Moura de Almeida; Lucas Jos&#233; Tachotti Pires; Jos&#233; Soares J&#250;nior; Wilson Ichiki; Wilson Andr&#233; Ichiki; L&#233;a Maria Macruz Ferreira Demarchi</bold>
          </p>
        </fn>
      </p>
      <p>Instituto do Cora&#231;&#227;o (InCor) HC-FMUSP, S&#227;o Paulo, SP - Brazil</p>
      <p>Mailing address</p>
      <p><bold>Keywords:</bold> Heart failure; hypertrophy, left ventricular; hypertension; atrial fibrillation; amyloidosis.</p>
      <p>A 41-year-old man from the city of S&#227;o Paulo sought medical attention due to rapidly progressive dyspnea and generalized edema. The patient was aware of having arterial hypertension and left ventricular hypertrophy.</p>
      <p>The patient had remained asymptomatic until 33 years old when he started to present exertional dyspnea. He sought medical attention at the time and was diagnosed with enlarged cardiac area. The clinical picture remained stable until he was 35 years old (May 2001), when he presented an episode of tachycardic palpitations and precordial pain. He sought medical attention and atrial flutter was diagnosed. The echocardiogram (September 13, 2001) disclosed moderate left ventricular hypertrophy (LVH) and pericardial effusion; the coronary angiography (October 18, 2001) did not show coronary artery obstructions. He was prescribed amiodarone and was referred to our hospital.</p>
      <p>At physical examination (December 13, 2001), the patient presented heart rate (HR) of 68 bpm, blood pressure (BP) of 140/95 mmHg. The remainder of the physical examination did not show any other alterations or diagnostic findings.</p>
      <p>The electrocardiogram (December 18, 2001) disclosed sinus rhythm, HR of 78 bpm, duration of PR = 157 ms, QRS = 108 ms, QT = 414 ms, S&#194;QRS + 130&#186; shifted backward. The morphological analysis disclosed an increased P wave, QS in leads I, aVL and Q wave in lead V6. Right atrial overload, electrically inactive lateral area and ventricular repolarization alterations were diagnosed.</p>
      <p>Laboratory assessment (December 19, 2001) disclosed: hemoglobin - 15.5 g/dl; hematocrit - 46%; total cholesterol - 242 mg/dl; triglycerides - 241 mg/dl; fasting glycemia - 107 mg/dl and creatinine - 1.3 mg/dl.</p>
      <p>Treatment with amiodarone was withdrawn and atenolol was prescribed.</p>
      <p>The patient started to present worsening of exertional dyspnea. The worsening was associated with the use of atenolol, which was discontinued, and the patient restarted amiodarone, 200 mg/day.</p>
      <p>The patient was submitted to ergometric test (February 21, 2003). At basal condition, the HR was 124 bpm and BP was 134/98 mmHg; after 2 minutes and 45 seconds of exertion, these parameters were 192 bpm and 158/94 mmHg. He started to present atrial fibrillation and nonsustained ventricular tachycardia during exertion.</p>
      <p>The Holter ECG recording (February 21, 2003) disclosed rhythm of atrial fibrillation, 202 isolated ventricular extrasystoles and an episode of nonsustained ventricular tachycardia with 4 beats and HR of 155 bpm.</p>
      <p>The echocardiogram (2003) disclosed enlarged left and right atria, asymmetric septal hypertrophy and normal left ventricular ejection fraction (LVEF) (<xref ref-type="table" rid="tab1-body3">Table 1</xref>).</p>
      <table-wrap id="tab1-body3">
        <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gt01-en.jpg"/></table-wrap>
      <p>Enalapril (5 mg), amiodarone (200 mg) and warfarin (5 mg) were prescribed.</p>
      <p>The symptoms abated; the exertional dyspnea persisted, as well as occasional episodes of palpitations, throughout two years. Subsequently, the dyspnea presented rapid increase, which started to occur even with the patient at rest. After one month, the patient had not improved and sought medical attention.</p>
      <p>At physical examination (June 3, 2004), the patient presented HR of 98 bpm, 24 breaths per minute, BP of 140/110 mmHg, increased jugular venous pressure, rales in the left hemithorax. Heart assessment disclosed arrhythmic beats, muffled heart sounds and systolic murmur +++/4+ in the aortic area. The liver was palpable at 2 cm from the right costal margin and the patient presented ++/4+ lower-limb edema.</p>
      <p>The chest X-ray showed an enlarged cardiac area with a round shape.</p>
      <p>The electrocardiogram (June 5, 2004) showed atrial flutter, HR of 79 bpm, low voltage of the QRS complex in the frontal plane, QRS axis shifted to the right and forward and decrease of the left ventricular potentials, suggesting right ventricular overload and an electrically inactive area in the lateral wall (<xref ref-type="fig" rid="en_a21fig01m-body3">Figure 1</xref>).</p>
      <p content-type="asset">
        <fig id="en_a21fig01m-body3">
          <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf01-en.jpg"/></fig>
      </p>
      <p>The echocardiogram (June 3, 2004) showed that the dimensions of the left ventricle (LV) and left atrium (LA) were similar to the previously measured ones, in addition to right ventricle (RV) hypertrophy and large pericardial effusion, without signs of cardiac restriction or cardiac tamponade (<xref ref-type="table" rid="tab1-body3">Table 1</xref>).</p>
      <p>Pericardial drainage and biopsy were indicated. At the intervention (June 5, 2004), 450 ml of citrine-yellow fluid was drained. The anatomopathological analysis of the pericardial fragments disclosed slight fibrosis and neovascularization of the pericardium, with no evidence of neoplastic cells or inflammatory infiltrate.</p>
      <p>The control echocardiogram (June 15, 2004) disclosed slight pericardial effusion. The patient presented improvement of the dyspnea and was discharged from the hospital (June 15, 2004).</p>
      <p>The mapping of the myocardial thickness by echocardiogram (June 4, 2007) disclosed the following measurements: anterior (basal 17 mm, mean 19 mm), anteroseptal (basal 20 mm, mean 22 mm), inferoseptal (basal 15 mm, mean 16 mm), inferior (basal and mean 11 mm) and inferolateral (basal 12, mean 13 mm), anterolateral (basal 11 mm, mean 15 mm), apical-septal 14 mm, apical-lateral 14 mm, apical cap 12 mm. The high-resolution electrocardiogram (July 26, 2007) disclosed QRS enlargement - standard QRS duration: 140 ms; filtered QRS duration: 130 ms; duration &lt; 40 mV 14 ms; and absence of low-amplitude late potentials in the final 40 ms, 61,7 mV.</p>
      <p>The dyspnea at moderate exertion remained stable for 4 more years, until it progressed to dyspnea at rest in the decubitus position in May 2008, along with generalized edema. After twenty days, as there was no improvement, the patient once again sought medical attention (June 6, 2006).</p>
      <p>At physical examination (June 6, 2008), the patient showed regular general status, with a pulse rate of 90 bpm and BP of 70/50 mmHg. The jugular venous pressure was high. Pulmonary assessment was normal. Heart assessment showed muffled heart sounds and no murmurs. The abdomen was globular and the patient presented ascites, in addition to ++++/4+scrotal and lower-limb edema.</p>
      <p>The ECG (June 6, 08) disclosed atrial fibrillation, HR of 96 bpm, QRS duration of 143 ms, low-voltage QRS complex, S&#194;QRS + 130 forward, right bundle-branch block, with pure R wave in V1 and V2, and electrically inactive lateral area (<xref ref-type="fig" rid="en_a21fig02m-body3">Figure 2</xref>). The chest X-ray (June 6, 2008) disclosed global enlargement of the cardiac area, with no signs of pulmonary congestion.</p>
      <p content-type="asset">
        <fig id="en_a21fig02m-body3">
          <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf02-en.jpg"/></fig>
      </p>
      <p>The laboratory assessment (June 6, 08) showed hemoglobin=11.5 g/dl, hematocrit 34%, leukocytes 6,700/mm<sup>3</sup> (68% neutrophils, 1% eosinophils, 1% basophils, 13% lymphocytes and 17% monocytes), platelets = 161,000/mm<sup>3</sup>, urea = 67 mg/dl, creatinine = 2.3 mg/dl, potassium = 3.6 mEq/l, sodium = 136 mEq/l, INR prothrombin time = 2.7, activated prothrombin time ratio 1.57, MB-fraction creatine phosphokinase = 3.73 ng/ml and troponin I = 0.21 ng/ml.</p>
      <p>The echocardiogram (June 11, 08) showed LV and RV hypokinesia and marked tricuspid regurgitation and moderate pericardial effusion (<xref ref-type="table" rid="tab1-body3">Table 1</xref>).</p>
      <p>The total abdominal ultrasonography (US) (June 12, 08) showed no abnormalities in the urinary system, inferior vena cava and hepatic vein ectasia, moderate ascites, blunt liver edge and finely heterogeneous texture.</p>
      <p>The laboratory assessment (June 12, 2008) showed creatinine 2.94 mg/dl, urea 110 mg/dl, potassium 5.9 mEq/l, sodium 134 mEq/l.</p>
      <p>The ventilation and pulmonary perfusion scintigraphy (June 16, 2008) was considered as being low-probability for pulmonary thromboembolism.</p>
      <p>The cardiac scintigraphy with technetium pyrophosphate (June 20, 2008) showed slight to moderate diffuse uptake in the myocardium (<xref ref-type="fig" rid="fig3-body3">Figures 3</xref> and <xref ref-type="fig" rid="fig4-body3">4</xref>).</p>
      <fig id="fig3-body3">
        <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf03-en.jpg"/></fig>
      <fig id="fig4-body3">
        <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf04-en.jpg"/></fig>
      <p>The cardiac magnetic resonance (June 27, 2006) showed marked biatrial dilatation; ventricular chambers with normal dimensions; slightmild left ventricular dysfunction due to diffuse hypokinesis; normal right ventricular function. There was marked tricuspid regurgitation and moderate pericardial effusion, bilateral pleural effusion and no thrombi. The findings were considered compatible with amyloidosis.</p>
      <p>The screening for Bence Jones protein in urine was negative.</p>
      <p>During patient evolution, the echocardiogram (July 11, 08) disclosed marked pericardial effusion (<xref ref-type="table" rid="tab1-body3">Table 1</xref>).</p>
      <p>In spite of the treatment with diuretics and inotropic drugs by IV route, the patient presented marked worsening in the clinical picture, with generalized edema, pleural effusion and pericardial effusion. A pericardial drainage was carried out, in addition to bilateral paracentesis thoracis, without complications (July 18, 2008).</p>
      <p>The patient presented coughing with purulent expectoration. Gram negative cocci were identified in the left pleural fluid. Antibiotic therapy with oxacillin and ceftriaxone (July 21, 2008) was started and subsequently substituted by tazobactam and vancomycin. The total abdominal US (July 22, 2008) disclosed hepatomegaly with normal shape and borders and blunt edges; the intra and extra-hepatic bile ducts were normal and the patient presented homogenous splenomegaly; moderate ascites was present. The kidneys were normal.</p>
      <p>The laboratory assessment (July 26, 2008) showed hemoglobin = 10.5 g/dl, hematocrit = 33%, leukocytes = 36,400/mm<sup>3</sup> (3% promyelocytes, 2% myelocytes, 8% metamyelocytes, 9% band cells, 63% segmented, 2% eosinophils, 1% basophils, 3% lymphocytes and 9% monocytes), platelets = 102,000/mm<sup>3</sup>, urea = 77 mg/dl, creatinine = 3 mg/dl, bilirubin = 7.8 mg/dl (direct = 6.6 mg/dl), alkaline phosphatase = 107 UI/l, gamma GT = 215 UI/l, aspartate aminotransferase = 47 UI/ml, alanine aminotransferase = 45 UI/l, C-reactive protein = 163 mg/l, arterial lactate = 52 mg/dl, prothrombin time (INR) = 2.1, TTPA ratio =1.5, arterial gasometry: pH 7.20, pCO<sub>2</sub> 39.5 mmHg, pO<sub>2</sub> 75.7 mmHg, O<sub>2</sub> saturation = 92.5%, bicarbonate = 14.8 mEq/l and base excess = -12.1mEq/l.</p>
      <p>In spite of the therapeutic measures, the patient developed septic shock staring on July 23, 2008; multiple organ failure ensued and the patient died due to asystole (July 27, 2008).</p>
      <p>
        <bold>Clinical aspects</bold>
      </p>
      <p>The patient, at the initial clinical picture at 33 years, complained of exertional dyspnea. At that time, it was important to try to define the most probable origin of the complaint. When it is the result of cardiopathy, dyspnea is associated with the increase in pulmonary capillary pressure, with consequent secondary interstitial congestion. Other potential causes of dyspnea can be pulmonary and thyroid causes, anemia, etc<sup>1,2</sup>. The presence of cardiac enlargement at the chest x-ray increaseds, at thatis moment, the probability of cardiac origin.</p>
      <p>Therefore, this is a patient with heart failure (HF), which could be caused by left ventricular systolic (LV ejection fraction [LVEF] &lt; 50%) or diastolic dysfunction (abnormal difficulty in LV diastolic filling)<sup>3</sup>.</p>
      <p>Diastolic dysfunction is the cause of HF in 40 to 50% of the patients. The diagnosis of HF with preserved EF (HFPEF) and diastolic dysfunction is established with the simultaneous presence of three factors: signs or symptoms of congestive HF; normal or slightly decreased LVEF; and objective evidence of LV diastolic dysfunction: abnormal LV relaxation and filling, abnormal diastolic distensibility or diastolic stiffness. The evidence of diastolic dysfunction can be obtained from hemodynamic data, natriuretic peptide levels, echocardiographic and tissue Doppler data<sup>4</sup>.</p>
      <p>The evolution with precordial pain and palpitations after two years, without significant alterations at the physical examination, with ventricular hypertrophy and normal EF at the echocardiogram, in addition to the pericardial effusion and absence of coronary disease, raises the possibility of hypertensive heart disease, myocarditis accompanied by pericardial involvement, hypertrophic cardiomyopathy (HCM) and restrictive syndromes, such as deposition diseases.</p>
      <p>The hypertensive heart disease can be defined as the result of the LV overload caused by the increase in BP and total peripheral vascular resistance. In this case, this is a young patient with LV hypertrophy (LVH) that developed HFPEF. As a consequence of the LVH, one can observe the increased incidence of some arrhythmias, such as ventricular extrasystoles, complex ventricular arrhythmias<sup>5</sup> and atrial fibrillation (AF), which would justify the tachyarrhythmias presented by the patient.</p>
      <p>The electrocardiogram (ECG), for the diagnosis of LVH, is a method with little sensitivity, albeit highly specific; however, the findings of the patient discussed herein do not meet these criteria. As for the echocardiogram, it is a low-cost method and considered the noninvasive method of choice for the diagnosis of increased cardiac mass. One could consider investigating secondary hypertension, as this was a young patient with LVH. However, in this case, as the patient apparently achieved BP control using only 5 mg of enalapril, thus attaining easy BPO control, as well as taking into account the patient evolution and the fact that the hypertrophy was clearly asymmetric, the hypothesis of hypertensive heart disease should be ruled out<sup>6,7</sup>.</p>
      <p>The myocardites, which are more often caused by viral agents<sup>8</sup>, present a broad spectrum of clinical presentation, which varies from subclinical or oligosymptomatic pictures to sudden cardiac death. Infection by some specific agents might be associated with less frequent presentations, such as the phenotype of hypertrophic cardiomyopathy without ventricular dysfunction - initially presented by this patient - which can be caused the hepatitis C virus, with a higher prevalence among Asian country populations<sup>9</sup>. Additionally, in fulminant myocarditis, characterized by a very severe acute presentation that includes cardiogenic shock, the echocardiographic assessment discloses an increase in the septal thickness with a lower increase in the ventricular diameters.</p>
      <p>The presence of arrhythmias associated with myocardial alterations is also frequent in myocardites and very often necessitates specific treatment, and/or being an indicator of possible unfavorable disease evolution, as in giant-cell myocarditis. In this specific type of myocardial inflammation, however, a shorter-duration history would be expected - differently from the present case - as the patients present poor prognosis, with a mean survival of less than 6 months and very frequent need for heart transplant when they survive the acute phase<sup>8</sup>.</p>
      <p>The active chronic myocarditis, in turn, would characteristically present a longer and more insidious evolution, usually with a phenotypic manifestation of dilated cardiomyopathy, with mortality rates that are as high as 56% in four years. Pericardial involvement can also occur, associated with the myocardites<sup>8</sup>.</p>
      <p>Another hypothesis for the case would be restrictive and infiltrative cardiomyopathies, which are characterized by limitation in ventricular filling and ventricular stiffness, with normal or slightly dilated ventricles and significant atrial dilatation<sup>9</sup>. Ventricular thickness is normal or increased, depending on the etiology. The symptoms can be caused by RV failure, which manifests with increased jugular venous pressure, peripheral edema and ascites and/or LV failure, causing dyspnea and pulmonary edema<sup>10,11</sup>. The restrictive cardiomyopathy is the rarest of all cardiomyopathies and amyloidosis is its most common form<sup>12</sup>.</p>
      <p>One of the causes of restrictive cardiomyopathy, sarcoidosis is a systemic granulomatous disease of unknown etiology, characterized by the involvement of several tissues by non-caseous granulomas<sup>13</sup>. The primary cardiac involvement is rare and the clinical manifestations appear in less than 5% of the patients and are characterized by conduction disorders, ventricular arrhythmias, syncope and sudden death. The direct myocardial involvement by the granulomas and scar tissue can manifest as dilated or restrictive cardiomyopathy, with a progressive course<sup>14,15</sup>. The ECG is nonspecific and can present T wave abnormalities, blockades or pathological Q waves. Other findings include pericarditis and cor pulmonale.</p>
      <p>The echocardiogram can disclose ventricular wall thinning and increased echogenicity<sup>14,16</sup>. The cardiac magnetic resonance (CMR) is a highly sensitive and specific method for its diagnosis. The case presented herein showed only cardiac involvement, without the other manifestations of the disease and the CMR did not disclose suggestive alterations, which makes this diagnosis unlikely<sup>17</sup>.</p>
      <p>Fabry's disease is an X-linked recessive disorder that results from the deficiency of the lysosomal enzyme alpha-galactosidase A. In its classic form, it is characterized by marked skin, kidney and myocardial involvement, including the manifestation of angina pectoris and myocardial infarction, although in most cases the coronary arteries have normal angiographic aspect. There is an increase in the LV thickness, with preserved systolic function and slight diastolic dysfunction and mitral regurgitation. The CMR is adequate to differentiate Fabry's disease from other cardiomyopathies<sup>10,11</sup>. The present case did not present extracardiac manifestations compatible with the disease and the CMR result was suggestive of another disease.</p>
      <p>Hemochromatosis results from the deposition of iron in parenchymatous tissues, such as heart, liver, gonads and pancreas. Its classic presentation is the onset of heart failure, liver cirrhosis, erectile dysfunction, diabetes mellitus and arthritis. The cardiac involvement leads to a combined pattern of dilated cardiomyopathy and restrictive cardiomyopathy with systolic and diastolic dysfunctions. The ECG shows ST-segment and T-wave alterations and supraventricular arrhythmias.</p>
      <p>The echocardiogram shows ventricular wall thickening, dilatation and dysfunction. The markers of iron kinetics are altered<sup>10,11</sup>. The T*2 CMR acquisition technique can establish the diagnosis<sup>18</sup>.</p>
      <p>The present case did not present suggestive extracardiac manifestations and the complementary examinations were not compatible with hemochromatosis.</p>
      <p>The endomyocardial diseases manifest with endocardial fibrosis that obliterates the ventricular apex and subvalvular regions<sup>10,11</sup>. As observed, this is not the pattern verified in the present case.</p>
      <p>Amyloidosis is a deposition disease that can be classified according to the biochemical nature of the amyloid protein as primary, secondary, senile, familial amyloidosis and amyloidosis of patients with dialytic renal failure. It must be considered as a differential diagnosis in any patient older than 40 years with unexplained heart failure, nephrotic syndrome, peripheral neuropathy or hepatopathy. Secondary amyloidosis and the amyloidosis of chronic kidney patients rarely present cardiac involvement. The ECG shows atrioventricular blocks and low-voltage QRS complexes and the high-resolution ECG is valuable in predicting the risk of sudden death, differently from what occurs in cases of HCM. Similarly to this other disease, however, amyloid infiltration can also predispose to AF and ventricular arrhythmias<sup>10,11,19,20</sup>.</p>
      <p>The echocardiogram shows an increase in myocardial thickness, which has a granular aspect, atrial dilatation, pericardial and/or pleural effusion and diastolic dysfunction. The pericardial effusion does not usually develop into cardiac tamponade and the presence of RV dysfunction is an independent predictor of poor prognosis<sup>10,11</sup>. The 99mTechnetium pyrophosphate scintigraphy shows uptake proportional to the intensity of the amyloid deposition<sup>11</sup>. As this radionuclide is capable of binding to the calcium, the examination can be altered in other situations as well, such as calcifications and other deposition diseases. The CMR has high sensitivity and specificity that can vary from 75% to 94%, when a pattern characterized by global and heterogeneous subendocardial late enhancement with gadolinium is found<sup>17,21,22</sup>, whereas the biopsy characterizes the amyloid substance and confirms the suspected amyloidosis.</p>
      <p>In the present case, initially, the diagnosis of amyloidosis seemed unlikely due to the patient's age and the ECG results. However, during the case evolution, the change in the electrocardiographic pattern was closer to the one commonly seen in cases of amyloidosis (low voltage); nevertheless, it was not possible to establish whether that occurred solely due to the pericardial effusion. Moreover, the screening for Bence Jones protein was negative. On the other hand, the patient presented severe restrictive syndrome and a pyrophosphate scintigraphy and CMR were performed, which are compatible with this diagnosis. Therefore, it would be possible to consider cardiac amyloidosis, in its primary form, as the diagnosis of the present case.</p>
      <p>A differential diagnosis of restrictive cardiomyopathy is constrictive pericarditis, characterized by pericardial fibrosis that prevents the filling of the cardiac chambers. Systemic venous congestion occurs, as well as a decrease in the cardiac index. The ECG normally shows unspecific alterations in the T wave and decreased voltage, in addition to signs of left atrial overload or AF. The chest X-ray shows right atrial enlargement and the echocardiogram can disclose pericardial calcifications and pericardial effusion. However the present case showed increased ventricular wall thickness, pulmonary artery systolic pressure &gt; 50 mmHg and no pericardial thickening at the CMR, all suggestive of restrictive, not constrictive, syndrome<sup>10,11</sup>.</p>
      <p>Finally, the HCM constitutes the genetic heart disease with the highest prevalence<sup>23</sup> and the most common cause of sudden death in young people<sup>24</sup>. An asymmetric pattern of hypertrophy is characteristic of the disease and 70% to 75% of the cases present echocardiographic evidence of diffuse hypertrophy of the ventricular septum and the anterolateral wall, as well as a description of right ventricular hypertrophy in some patients<sup>25</sup>. The clinical manifestations can appear at any age, with the diagnosis being more frequent during adolescence and the start of adult life.</p>
      <p>The disarray of the myocardial structure induced by the disease, associated with the increase in the ventricular mass and the alterations present in the coronary microvasculature lead to silent myocardial ischemia, with the formation of areas of fibrosis that can correspond to electrically unstable regions, from which ventricular arrhythmias can originate. Additionally, these areas of fibrosis, associated with regional hypertrophy (generally, septal), can lead to ECG alterations with atrial overload, for instance, R waves in V1, decrease in R waves and appearance of Q waves in lateral wall leads (DI, aVL, V5 and V6), alterations in ventricular repolarization and, in cases of lateral-wall fibrosis, rightward shift of axis, as it can be observed in the present case. During disease evolution, QRS enlargement can also occur, which is compatible with the present case<sup>26</sup>.</p>
      <p>The patients can present LV outflow tract obstruction, which is related to the development of HF clinical picture, a higher rate of cardiovascular death and a higher risk of sudden death<sup>3</sup>, which can be reduced with the use of beta-blockers and increased, among other situations, in the presence of ventricular extrasystoles (VE) and in Valsalva maneuver.</p>
      <p>The patient presented clinical worsening after the withdrawal of amiodarone and the start of atenolol use. If the diagnosis of HCM had been correct and therefore, the use of beta-blocker had been correctly indicated, the amiodarone withdrawal might have been associated with an increase in the VE frequency, with a consequent increase in the subaortic gradient, which might have led to the onset of an obstructive component in the disease, thus generating the worsening in the dyspnea symptom. Another possible cause of the worsening with amiodarone withdrawal might have been the higher incidence of supraventricular paroxysmal arrhythmias, such as AF, known to be associated with the clinical worsening in these patients, with a worse prognosis<sup>23,26</sup>. It is known that the incidence of supraventricular arrhythmias, including AF, in Holter recordings can be as high as 30% in adults<sup>26</sup>. The presence of AF in this population, even at the first or the second paroxysmal episode, is capable of generating thrombus formation and cardioembolic phenomena, resulting in the indication of anticoagulation for these patients, with a low threshold for its start<sup>24,27</sup>.</p>
      <p>Ten to 15% of the patients develop limiting heart failure (New York Heart Association functional class III or IV), and only 3% manifest advanced disease with LVEF &lt; 50%<sup>28</sup>. A study published in 2007 showed that, among 1,226 patients with a diagnosis of HCM, the prevalence of the restrictive phenotype was 1.5%<sup>29</sup>.</p>
      <p>The patients with the studied phenotype presented higher diastolic dysfunction and higher left atrial diameter, in addition to lower tolerance to exercise and worse prognosis, with a 5-year survival of 56% - versus 90% in those without the restrictive phenotype (p=0.008) - with 42% of the cases presenting signs of right heart failure, such as ascites, abdominal discomfort and edema. There was also a higher tendency to the development of AF or atrial flutter and higher rates of cerebrovascular accident. It can be observed that during disease evolution, the patient described herein presented several characteristics that were compatible with this disease phenotype.</p>
      <p>Due to the possibility of sudden death, previous studies have defined risk markers, used in the stratification of these patients. Those diagnosed before 14 years of age present a higher risk. Other factors include: personal history of syncope or reverted sudden death; severe hypertrophy (&gt; 30 mm)<sup>30</sup>; presence of non-sustained ventricular tachycardia (NSVT) at Holter monitoring; abnormal BP behavior at exertion - decrease in BP or increase &lt; 25 mmHg in the systolic pressure<sup>26</sup>. The high-resolution ECG, the analysis of the QT interval dispersion and of the heart rate variability present low predictive acuracy<sup>31</sup>. In the present case, the patient presented, among the listed risk factors, NSVT at Holter monitoring and did not present a BP curve that could be assessed at the ergometric test, considering the low workload.</p>
      <p>The clinical picture presented a progressive feature since the diagnosis, characterized by three important decompensation episodes, with increasingly more significant clinical, electrocardiographic and echocardiographic alterations. At the last hospital admission, the patient developed a biventricular systolic dysfunction, marked pericardial effusion, edema, ascites and cardiogenic shock, accompanied by kidney failure, coagulopathy and pulmonary infection complicated by septic shock, which resulted in the patient's death.</p>
      <p>Considering the age at the initial presentation, the clinical alterations observed throughout the years of evolution, the alterations at the complementary examinations and the characteristics of each one of the diseases presented during this discussion, we consider HCM as the main diagnostic hypothesis in the present case.</p>
      <p>Dr. Rafael Moura de Almeida</p>
      <p> and Dr. Lucas Jos&#233; Tachotti Pires</p>
      <p>
        <bold>Diagnostic hypothesis</bold>
      </p>
      <p>Restrictive syndrome secondary to hypertrophic cardiomyopathy.</p>
      <p>Dr. Rafael Moura de Almeida</p>
      <p> and Dr. Lucas Jos&#233; Tachotti Pires</p>
      <p>
        <bold>Scintigraphy</bold>
      </p>
      <p>Scintigraphy with 99mTc-pyrophosphate was performed on June 20, 2008 (<xref ref-type="fig" rid="fig3-body3">Figures 3</xref> and <xref ref-type="fig" rid="fig4-body3">4</xref>). The chest scintigraphy images, performed 3 hours after the IV administration of 99mTc-pyrophosphate, obtained on the anterior view (<xref ref-type="fig" rid="fig3-body3">Figure 3</xref>) and left anterior oblique view at 60&#186; demonstrate slight/moderate diffuse cardiac uptake.</p>
      <p>The 99mTc-pyrophosphate binds to intracellular calcium, which accumulates in the cells due to sarcolemma alterations. It is worth mentioning that the normal myocardium does not present 99mTc-pyrophosphate uptake. This examination was frequently used in the past to evaluate acute myocardial infarction, where the classic pattern is that of focal uptake in the affected wall. The diffuse uptake is a rare and little specific finding, generally related to diseases that affect the heart diffusely, such as amyloidosis, sarcoidosis, perimyocarditis, endocarditis or subendocardial infarction. In amyloidosis, the degree of uptake is related to the degree of myocardial thickening, thus with prognostic implications<sup>32,33</sup>. In the present case, the diffuse uptake in hypertrophic cardiomyopathy is not expected and might be related to the findings of the necropsy of subendocardial infarction and/or pericarditis.</p>
      <p>Dr. Jos&#233; Soares Junior, Dr. Wilson Ichiki</p>
      <p> and Dr. Wilson Andr&#233; Ichiki</p>
      <p>
        <bold>Necropsy</bold>
      </p>
      <p>Approximately 250 ml of blood, as well as blood clots, leaked out at the opening of the pericardial sac. Diffuse fibrinous pericarditis was observed. The heart weighed 510 g (normal: 300-350 g) and presented increased volume of the four cardiac chambers. There was moderate dilatation of the right ventricle and of the atria. The ventricles presented moderate and symmetric hypertrophy, in relation to the thickness of the ventricular septum and the LV free wall = 1.2, without cavitary obstruction. There were extensive areas of fibrosis in the LV myocardium (<xref ref-type="fig" rid="fig5-body3">Figures 5</xref> and <xref ref-type="fig" rid="fig6-body3">6</xref>). The endocardium of both ventricles was narrow, smooth and shiny. The right auricle exhibited a small mixed thrombus, in the process of formation. No abnormalities were observed in the atrioventricular or ventricular-arterial valves. The study of the coronary arteries showed an intramyocardial trajectory ("myocardial bridge") from the 2<sup>nd</sup> to the 4<sup>th</sup> cm of the left interventricular branch (<xref ref-type="fig" rid="fig7-body3">Figure 7</xref>) and the histological analysis showed mild coronary atherosclerosis, with a maximum 30% of obstruction of the lumen of the main coronary arteries.</p>
      <fig id="fig5-body3">
        <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf05-en.jpg"/></fig>
      <fig id="fig6-body3">
        <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf06-en.jpg"/></fig>
      <fig id="fig7-body3">
        <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf07-en.jpg"/></fig>
      <p>Histological sections of the ventricles showed diffuse myocardial hypertrophy, spatial disarray of cardiomyocytes and of the cardiac fiber bundles in more than 20% of the sampled areas, diffuse interstitial fibrosis from the subendocardial to the subepicardial region and intramural coronary artery wall thickening due to intima-media proliferation of smooth muscle cells (<xref ref-type="fig" rid="en_a21fig08m-body3">Figure 8</xref>). Although present in both ventricles, these alterations were more marked in the ventricular septum and the LV free wall. The histochemical analysis for the presence of amyloid substance and glycogen in the myocardium were negative. Considering the anatomopathological findings of the necropsy, a diagnosis of restrictive hypertrophic cardiomyopathy, without cavitary obstruction, was attained. Chronic passive lung, liver and spleen congestion was also observed, as well as generalized subcutaneous tissue edema, consequent to congestive heart failure.</p>
      <p content-type="asset">
        <fig id="en_a21fig08m-body3">
          <graphic xlink:href="1678-4170-abc-95-05-e112-00021-gf08-en.jpg"/></fig>
      </p>
      <p>The other organs showed alterations secondary to shock, represented by diffuse alveolar injury and intra-alveolar hemorrhage in the lungs, acute tubular necrosis in the kidneys, centrilobular liver necrosis and recent, small and multifocal subendocardial infarctions.</p>
      <p>The lungs presented localized areas of bronchopneumonia at the initial stage. However, no morphological alterations suggestive of infection were observed in other organs. The presence of blood and blood clots in the pericardial sac seems to be one more final event, the result of the resuscitation maneuvers.</p>
      <p>The cause of death was multiple-organ failure due to shock, predominantly cardiogenic shock and aggravated by the pulmonary infection.</p>
      <p>
        <bold>Dr. L&#233;a Maria Macruz Ferreira Demarchi</bold>
      </p>
      <p>
        <bold>Anatomopathological diagnoses</bold>
      </p>
      <p>1) Symmetric and non-obstructive hypertrophic cardiomyopathy, on-ce; 2) Congestive heart failure; 3) Mixed (cardiogenic/septic) shock; 4) Multiple-organ failure.</p>
      <p>
        <bold>Dr. L&#233;a Maria Macruz Ferreira Demarchi</bold>
      </p>
      <p>
        <bold>Comment</bold>
      </p>
      <p>The hypertrophic cardiomyopathy (HCM) is defined as a genetic primary cardiomyopathy, morphologically characterized by non-dilated hypertrophy of the left ventricle, in the absence of another systemic or heart disease capable of causing such ventricular alteration, such as systemic arterial hypertension and aortic valve stenosis<sup>34</sup>.</p>
      <p>It has a comprehensive clinical spectrum and broad morphological and symptomatic variability and risk of complications such as sudden death and heart failure<sup>35</sup>.</p>
      <p>The main anatomic characteristics of the HCM were obtained from the observation of necropsy data and are thus defined<sup>34</sup>: myocardial hypertrophy, spatial disarray of cardiomyocytes, intramural coronary arteries with obstructive alterations and myocardial fibrosis.</p>
      <p>The myocardial hypertrophy can be asymmetric or symmetric. The most common form of presentation is the asymmetric one, characterized by more marked hypertrophy of the ventricular septum, with the ratio between the ventricular septum and the LV lateral free wall <underline>&gt;</underline> 1.3<sup>36</sup>.</p>
      <p>When located in the basal portion of the ventricular septum, the hypertrophy causes left ventricular outflow tract obstruction and, consequently, thickening of the mitral anterior cusp and subaortic septal endocardial fibrosis. Due to the constant friction between the valve leaflet and the septal endocardium, the endocardial fibrosis can acquire the format of the mirror image of the anterior cusp of the mitral valve.</p>
      <p>The symmetric form is characterized by concentric hypertrophy of the left ventricle, without obstruction of the ventricular outflow tract.</p>
      <p>In HCM, the spatial disarray of the cardiomyocytes must be present in more than 20% of the histologically sampled areas<sup>37</sup> and is characterized by multiple and chaotic intercellular connections, as right and oblique angles<sup>34</sup>. It can be found in any wall of both ventricles and more often occupies large portions of the LV. Extensive areas of disarray are described in young patients that died due to the disease<sup>34</sup>.</p>
      <p>The intramural coronary arteries present obstructive alterations characterized by thickening of the wall and lumen narrowing, due to the increase in collagen deposition in the intima and media layers. Such alterations, associated with the disproportion between the ventricular mass hypertrophy and the coronary circulation, result in myocardial ischemia and consequent fibrosis, which can be either focal or transmural<sup>34</sup>.</p>
      <p>Another frequent finding in HCM is the intramural trajectory or "myocardial bridge" of the anterior interventricular branch of the left coronary artery, which has also been observed in this patient, although its physiopathological meaning is yet to be fully clarified<sup>38</sup>.</p>
      <p>The contribution of the endomyocardial biopsy (EMB) for the diagnosis of hypertrophic cardiomyopathy is quite limited and, in the present case, it did not show myocardial disarray, but only cardiomyocyte hypertrophy. In HCM, the areas of disarray are frequently located in deeper regions of the ventricular wall, distant from the subendocardial region and, therefore, out of reach of the bioptome. However, the EMB is quite useful for the differential diagnosis with other causes of ventricular hypertrophy, such as amyloidosis, Pompe disease and even neoplasias<sup>37,39</sup>.</p>
      <p>The anatomopathological findings of the necropsy, associated with the clinical data and complementary examinations were crucial for the diagnosis of HCM in this patient.</p>
      <p>
        <bold>Dr. L&#233;a Maria Macruz Ferreira Demarchi</bold>
      </p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
